US20030108602A1 - Tablets and methods for modified release of hydrophilic and other active agents - Google Patents
Tablets and methods for modified release of hydrophilic and other active agents Download PDFInfo
- Publication number
- US20030108602A1 US20030108602A1 US10/191,979 US19197902A US2003108602A1 US 20030108602 A1 US20030108602 A1 US 20030108602A1 US 19197902 A US19197902 A US 19197902A US 2003108602 A1 US2003108602 A1 US 2003108602A1
- Authority
- US
- United States
- Prior art keywords
- tablet
- active agent
- particles
- poly
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 318
- 238000000034 method Methods 0.000 title claims abstract description 101
- 239000002245 particle Substances 0.000 claims abstract description 219
- 238000000576 coating method Methods 0.000 claims abstract description 156
- 239000011248 coating agent Substances 0.000 claims abstract description 137
- 239000000463 material Substances 0.000 claims abstract description 137
- 229920000642 polymer Polymers 0.000 claims description 77
- 238000001879 gelation Methods 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 72
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 71
- 239000002202 Polyethylene glycol Substances 0.000 claims description 70
- 229920001223 polyethylene glycol Polymers 0.000 claims description 70
- 239000008187 granular material Substances 0.000 claims description 60
- 239000011159 matrix material Substances 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 55
- -1 poly(vinylacetate phthalate) Polymers 0.000 claims description 52
- 238000009472 formulation Methods 0.000 claims description 40
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 33
- 239000013078 crystal Substances 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 22
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 17
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 17
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 17
- 238000013268 sustained release Methods 0.000 claims description 15
- 239000012730 sustained-release form Substances 0.000 claims description 14
- 238000009826 distribution Methods 0.000 claims description 13
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 7
- 239000011118 polyvinyl acetate Substances 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 229920001059 synthetic polymer Polymers 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940117958 vinyl acetate Drugs 0.000 claims description 4
- 229920005615 natural polymer Polymers 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 236
- 229940079593 drug Drugs 0.000 description 75
- 239000003814 drug Substances 0.000 description 75
- 239000008188 pellet Substances 0.000 description 46
- 230000008569 process Effects 0.000 description 40
- 238000005469 granulation Methods 0.000 description 35
- 230000003179 granulation Effects 0.000 description 35
- 238000007906 compression Methods 0.000 description 27
- 230000006835 compression Effects 0.000 description 27
- 239000011230 binding agent Substances 0.000 description 24
- 210000001035 gastrointestinal tract Anatomy 0.000 description 24
- SURWTGAXEIEOGY-GNAZCLTHSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrochloride Chemical compound Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 SURWTGAXEIEOGY-GNAZCLTHSA-N 0.000 description 22
- 238000009477 fluid bed granulation Methods 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 239000011324 bead Substances 0.000 description 19
- 239000000843 powder Substances 0.000 description 18
- 210000001072 colon Anatomy 0.000 description 15
- 238000004090 dissolution Methods 0.000 description 15
- 239000000499 gel Substances 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical group O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 229960001314 cevimeline Drugs 0.000 description 9
- WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 9
- 238000007908 dry granulation Methods 0.000 description 9
- 230000003628 erosive effect Effects 0.000 description 9
- 238000005453 pelletization Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000000541 pulsatile effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003801 milling Methods 0.000 description 7
- 230000000704 physical effect Effects 0.000 description 7
- 238000009490 roller compaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 229920001688 coating polymer Polymers 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000002249 digestive system Anatomy 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000013563 matrix tablet Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 238000009491 slugging Methods 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005354 coacervation Methods 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229960002745 cevimeline hydrochloride Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000012695 Interfacial polymerization Methods 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002396 Polyurea Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 2
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XEMPUKIZUCIZEY-YSCHMLPRSA-N Barnidipine hydrochloride Chemical compound Cl.C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 XEMPUKIZUCIZEY-YSCHMLPRSA-N 0.000 description 1
- MEAHDXWXNNDSAK-UHFFFAOYSA-N Bifemelane hydrochloride Chemical compound [Cl-].C[NH2+]CCCCOC1=CC=CC=C1CC1=CC=CC=C1 MEAHDXWXNNDSAK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- HMSYAPGFKGSXAJ-PAHGNTJYSA-N Mocimycin Chemical compound C(/[C@H]1O[C@H]([C@H]([C@H]1O)O)[C@H](C)[C@H](OC)C(/C)=C/C=C/CNC(=O)[C@@H](CC)[C@]1(O)[C@@H]([C@H](O)C(C)(C)[C@H](\C=C\C=C/C)O1)O)=C\C=C\C=C(/C)C(=O)C1=C(O)NC=CC1=O HMSYAPGFKGSXAJ-PAHGNTJYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- RJTOSFZZYBCYTM-UHFFFAOYSA-N Moperone hydrochloride Chemical compound [Cl-].C1=CC(C)=CC=C1C1(O)CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 RJTOSFZZYBCYTM-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 239000004614 Process Aid Substances 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- OTFDPNXIVHBTKW-UHFFFAOYSA-N Tiapride hydrochloride Chemical compound [Cl-].CC[NH+](CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC OTFDPNXIVHBTKW-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229950010351 amosulalol Drugs 0.000 description 1
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004933 bifemelane Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960003880 bromisoval Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- ASOJLQIBBYOFDE-HCHBIZCOSA-N chembl2106443 Chemical compound C(/[C@H]1O[C@H]([C@H]([C@H]1O)O)[C@H](C)[C@H](OC)C(/C)=C/C=C/CNC(=O)[C@@H](CC)[C@]1(O)[C@@H]([C@H](O[C@H]2[C@@H]([C@H](OC)[C@H](O[C@H]3[C@@H]([C@H](O)[C@@H](OC)[C@H](C)O3)OC)[C@@H](C)O2)O)C(C)(C)[C@H](\C=C\C=C\C)O1)O)=C\C=C\C=C(/C)C(=O)C1=C(O)C=CN(C)C1=O ASOJLQIBBYOFDE-HCHBIZCOSA-N 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 229960005452 cobamamide Drugs 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229950003445 efrotomycin Drugs 0.000 description 1
- 238000004924 electrostatic deposition Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229950004649 etomidoline Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- NTAHMPNXQOYXSX-WKSONYIQSA-N goldinodox Chemical compound C(/[C@H]1O[C@H]([C@H]([C@H]1O)O)[C@H](C)[C@H](OC)C(/C)=C/C=C/CNC(=O)[C@@H](CC)[C@]1(O)[C@@H]([C@H](O)C(C)(C)[C@H](\C=C\C=C/C)O1)O)=C\C=C\C=C(/C)C(=O)C1=C(O)C=CN(C)C1=O NTAHMPNXQOYXSX-WKSONYIQSA-N 0.000 description 1
- NTAHMPNXQOYXSX-UHFFFAOYSA-N goldinomycin Natural products CCC(C(=O)NCC=CC=C(C)C(OC)C(C)C1OC(C=CC=CC=C(C)C(=O)c2c(O)ccn(C)c2=O)C(O)C1O)C1(O)OC(C=CC=CC)C(C)(C)C(O)C1O NTAHMPNXQOYXSX-UHFFFAOYSA-N 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 1
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950008095 mocimycin Drugs 0.000 description 1
- HMSYAPGFKGSXAJ-KNHRXMRASA-N mocimycin Natural products C([C@H]1O[C@H]([C@H]([C@H]1O)O)[C@H](C)[C@H](OC)C(C)=CC=CCNC(=O)[C@@H](CC)[C@]1(O)[C@@H]([C@H](O)C(C)(C)[C@H](C=CC=CC)O1)O)=CC=CC=C(C)C(=O)C1=C(O)NC=CC1=O HMSYAPGFKGSXAJ-KNHRXMRASA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960000758 moperone Drugs 0.000 description 1
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical group C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 description 1
- LLJDJQYGZBQFIF-UHFFFAOYSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[1-(2-oxo-1,3-oxathian-4-ylidene)ethyl]formamide Chemical compound C1COC(=O)SC1=C(C)N(C=O)CC1=CN=C(C)N=C1N LLJDJQYGZBQFIF-UHFFFAOYSA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- SUWYPNNPLSRNPS-UNTSEYQFSA-N plaunotol Chemical compound CC(C)=CCC\C(C)=C\CC\C(CO)=C\CC\C(C)=C\CO SUWYPNNPLSRNPS-UNTSEYQFSA-N 0.000 description 1
- 229950009291 plaunotol Drugs 0.000 description 1
- SUWYPNNPLSRNPS-UHFFFAOYSA-N plaunotol Natural products CC(C)=CCCC(C)=CCCC(CO)=CCCC(C)=CCO SUWYPNNPLSRNPS-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WVULZDFWPQCPPJ-UHFFFAOYSA-N potassium;hydrochloride Chemical compound Cl.[K] WVULZDFWPQCPPJ-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 description 1
- 229960002443 propafenone hydrochloride Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 229940018203 pyrilamine maleate Drugs 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical class O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- JP-A-62-120315 discloses a preparation obtained by compression-molding a drug, a hydrogel-forming water-soluble polymer and an enteric coating.
- JP-A-63-215620 discloses a hydrogel-type preparation with a core having a drug and a water-soluble polymer and an outer layer with a water-soluble polymer as a base.
- JP-B-40-2053 discloses a sustained-release preparation having a mixture of a drug and a high polymer of ethylene oxide and, as an optional component, a hydrophilic substance.
- Hydrophilic gel-forming preparations have been further developed so that they can provide a sustained release of orally ingested drugs throughout the digestive system, including in the lower digestive tract.
- EP 0 661 045 describes a preparation adapted to absorb water into its core to undergo substantially complete gelation during its stay in the upper digestive tract. As the tablet moves down the digestive system in the form of a gel to the lower digestive tract, the preparation swells and the gelled outer surface of the tablet erodes gradually releasing the drug.
- This type of oral tablet is capable of providing a sustained release of the drug throughout the digestive tract, including in the colon.
- the gel-forming preparations such as those described in the EP 0 661 045
- they may not be suitable for certain types of active agents, particularly when the active agents are unstable in the gel-forming preparations or may be released in a manner that is not desirable.
- improved forms of sustained release preparations which can continuously release an active agent throughout the digestive tract, regardless of the physical or chemical properties of the active agent.
- many situations may require that an active agent be delivered to the patient in a non-random or pulsatile manner, or, that the active agent be delivered to a particular anatomic compartment, e.g., the colon.
- the present invention provides, for the first time, a tablet and methods for making the tablet that comprises a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent from the tablet.
- These particles that comprise the active agent and the coating material are also referred to as “active agent-containing particle”, “coated particle” or “coated bead.”
- the gel-forming material forms a matrix (a “gel-forming matrix”) for the active agent-containing particles.
- the active agent-containing particle is formulated with a coating material so that it can modify or control the release of the active agent by, for example, slowing or inhibiting the passage of the active agent out of the tablet and into the digestive system.
- OCASTM oral controlled absorption system
- the release of the active agent from the tablet can be modified and controlled by the combination of two systems: 1) the gel-forming matrix; and 2) the coating material in contact with the active agent.
- the gel-forming matrix absorbs water to undergo substantially complete gelation during its stay in the upper digestive tract and moves down into the lower digestive tract undergoing constant erosion, continuously releasing the active agent-containing particles from the tablet. This erosion of the gel-forming matrix can control the release of the active agent-containing particles from the tablet.
- the coating material that is on or around the active agent provides another level of control in releasing the active agent from the tablet.
- the coating material can modify or control the rate of diffusion of the active agent through the gel matrix and out of the tablet.
- any type of active agents can be included in the tablets of the present invention. The selection of the active agent is not restricted to those which are released from the tablet in a favorable manner.
- the invention is particularly useful for an active agent that is hydrophilic.
- the erosion of the gel-forming matrix of the tablet precedes the diffusion of the active agent through the swollen gel layer of the tablet.
- the active agent release rate limiting step is typically the erosion of the gel-forming matrix. Therefore, with these active agents, the gel-forming matrix alone can provide enough control on-release of the active agent and can be used to design a sustained release of these active agents over, e.g., 12-24 hours.
- a hydrophilic active agent tends to diffuse out from the gel-forming matrix faster than the erosion of the swollen gel layer of the tablet.
- a tablet comprising a gel-forming matrix may be useful for water insoluble or less hydrophilic active agents, the gel-forming matrix may not provide for sufficient controlled release for the hydrophilic active agent.
- FIG. 9 illustrates this diffusion problem for a hydrophilic active agent.
- a tablet comprising Cevimeline HCl (having a high water solubility of about 766 mg/ml at 25° C.) and a gel-forming matrix comprising a polyethylene oxide polymer (PEO) and a polyethylene glycol (PEG) was prepared.
- the active agent Cevimeline HCl as purchased (without further treatment) was mixed with the gel-forming material.
- FIG. 9 shows the drug release profile from this conventional Cevimeline HCl matrix tablet. As shown in FIG. 9, substantially all of the drug was released in about 6-8 hours from the tablet. The tablet did not provide for sustained release of the drug over, e.g., 12-24 hours.
- a hydrophilic active agent such as Cevimeline HCl
- Cevimeline HCl is physically and/or chemically modified to control its release rate from the tablet.
- Preferred embodiments of the invention provide a tablet comprising a gel-forming material and a particle comprising a hydrophilic active agent, wherein the particle is formulated to modify release of the active agent from the tablet.
- the particle comprises a hydrophilic active agent in contact with a coating material (e.g., on or around the active agent).
- the coating material can slow or prevent the diffusion of the hydrophilic active agent out of the gel-forming matrix.
- Example 6C describes an embodiment of the present tablet which comprises Cevimeline HCl in contact with a coating material in a gel matrx.
- the release profiles of this modified Cevimeline HCl from the gel matrix tablet are much more gradual and linear than the release profile of unmodified Cevimeline HCl from the conventional matrix tablet shown in FIG. 9.
- FIGS. 9 and 10 are compared, it is clear that embodiments of the invention can provide a sustained release of a hydrophilic drug up to, e.g., 12-24 hours, compared to conventional gel matrix tablets without modification of the active agent.
- any suitable active agents including a less hydrophilic active agent or a hydrophobic active agent, can be incorporated into embodiments of the invention.
- embodiments of the invention are particularly useful for active agents that are unstable, or sensitive to moisture or oxidation.
- the active agent is an enzyme, it may lose its activity if it is in contact with water or the gel-forming material for a prolonged period of time.
- a physical and/or chemical barrier e.g., a coating
- these embodiments of the invention are capable of sustaining the efficacy of active agents for a prolonged period.
- One beneficial result is that the number of administrations can be reduced.
- an individual needs to take a tablet comprising an active agent, such as a drug, only once a day or twice a day.
- tablets can release a drug too quickly into the upper digestive tract of a person, resulting in undesirable side effects.
- Embodiment of the invention is capable of providing a constant concentration of the drug within the blood of a person. This may reduce potential side effects of the drug by suppressing rapid increases in blood concentration of the drug.
- the invention provides tablets and methods for making the tablets that can achieve programmable drug release profiles.
- the tablets can be designed to have pulsatile, delayed onset or any suitable predetermined release profile. In one embodiment, this is achieved by designing a multilayered tablet.
- different layers of the multilayered tablet can comprise different active agents, different amounts of active agent and/or different forms of active agent.
- different layers of the multilayered tablet can comprise different proportions of a polymer and a gelation facilitator agent, and/or different kinds of a polymer or a gelation facilitator agent.
- the multilayered tablet slowly dissolves in its passage through the digestive tract, it releases varying amounts of active agent (or different active agents) at different times, i.e., in different anatomical compartments (e.g., small intestine versus colon).
- active agent or different active agents
- one active agent (or form of the active agent) is released in the upper digestive tract (e.g., stomach or small intestine) and another active agent or a variation of the active agent is released in the lower digestive tract (e.g., large intestine or colon).
- the upper digestive tract e.g., stomach or small intestine
- another active agent or a variation of the active agent is released in the lower digestive tract (e.g., large intestine or colon).
- the invention provides a tablet comprising: at least one particle comprising a hydrophilic active agent in contact with a coating material to modify release of the active agent, and a gel-forming material comprising: a polymer; and a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C.
- the particle comprises an active agent and a coating material on or around the active agent.
- the hydrophilic active agent has a water solubility of at least about 30 mg/ml at a temperature of about 25° C.
- the hydrophilic active agent is a quinuclidine derivative or acetylcholine.
- the active agent-containing particle has a size between about 50 ⁇ m to about 5 mm, preferably between about 100 ⁇ m to about 3 mm, and more preferably between about 300 ⁇ m to about 2 mm.
- the tablet comprises a plurality of the active agent-containing particles and wherein the gel-forming material forms a matrix for the plurality of the particles.
- the active agent is in the form of a crystal or a granule, and/or the particle comprises a plurality of active agent crystals or granules.
- the coating material slows release of the active agent from the tablet.
- the coating material is flexible.
- the coating material is selected from the group consisting of a natural polymer, a semi-synthetic polymer, and a synthetic polymer.
- these polymers include chitosan, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, cellulose acetate membrane, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyacrylic acid, polyvinyl acetate, poly(vinylacetate phthalate), poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(lactic acid), poly(glycolic acid), poly(lactic/glycolic acid), poly(dimethyl silicone), poly(hydroxyethyl methacrylate), poly(ethylene/vinyl acetate), poly(ethylene/vinyl alcohol), or a mixture thereof.
- the coating material further comprises a plasticizer, a stabilizer or both.
- the polymer comprises a polyethylene oxide polymer.
- the gelation facilitator agent comprises a polyethylene glycol.
- the polymer to the gelation facilitator ratio is between about 1:9 to about 9:1 by weight, preferably between about 3:7 to about 7:3 by weight, more preferably between about 4:6 to about 6:4 by weight.
- the tablet has a hardness of at least about 2 kp.
- the tablet has a hardness between about 2 kp and about 10 kp.
- the tablet provides a sustained release of the active agent for at least about 12 hours.
- the tablet further comprises a non-hydrophilic active agent.
- the tablet comprises at least two different types of particles with different active agents.
- the particles in the tablet comprise at least two different types of particles with different coating materials.
- the distribution of the particles in the tablet is non-random.
- the tablet is a multilayered tablet.
- At least two of the layers of the multilayered tablet comprise a different amount of the particles or at least two different types of active agents.
- the particles in the tablet are concentrated at the core of the tablet.
- the polymer comprises a polyethylene oxide polymer and the gelation facilitator agent comprises a polyethylene glycol.
- the invention provides a method for producing a modified tablet, the method comprising: (1) mixing a formulation comprising: (a) at least one particle comprising a hydrophilic active agent in contact with a coating material to modify release of the active agent; (b) a polymer; and (c) a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C.; and (2) compressing the formulation to produce the tablet.
- any of the materials described herein can be used to produce a tablet.
- the particle comprises the active agent and a coating material on the active agent.
- the coating material is flexible so that it does not crack during compressing the formulation into the tablet.
- the coating material is hydrophobic.
- the particle is produced by spraying the coating material on the active agent.
- the polymer is granulated with the gelation facilitator agent in step (1).
- the polymer and the gelation facilitator agent are granulated with the active agent-containing particles in step (1).
- FIG. 1A illustrates one embodiment of tablet 101 comprising a gel-forming matrix 10 and particles 11 , wherein the particles comprise an active agent and a coating material in contact with the active agent.
- FIG. 1B illustrates an enlarged view of one embodiment of a particle 11 ( a ).
- the particle 11 ( a ) comprises an active agent 12 ( a ) and a coating material 13 ( a ) on and around the active agent.
- FIG. 1C illustrates an enlarged view of another embodiment of a particle 11 ( b ).
- the particle 11 ( b ) comprises a plurality of active agents 12 ( b ) and a coating material 13 ( b ) on and around the active agents.
- the particle 11 ( b ) also comprises a plurality of active agents 12 ( c ), wherein the coating material 13 ( b ) is on, but not necessarily around the active agents.
- FIG. 2A illustrates another embodiment of tablet 102 comprising a gel-forming matrix 10 and a plurality of different types of particles 11 , 16 and 17 .
- FIG. 2B illustrates an embodiment of multilayered tablet 103 comprising two layers.
- the core region 10 comprises particles 11 and the outer region 15 is devoid of particles.
- FIG. 2C illustrates another embodiment of multilayered tablet 104 comprising three layers.
- the core region 10 comprises one type of particles 11
- the intermediate region 14 comprises another type of particles 16
- the outer region 18 is devoid of particles.
- FIG. 3 illustrates an overview of one embodiment of active agent pelletization/granulation development schemes.
- FIG. 4 illustrates one embodiment of coating process schemes to make coated particles or beads comprising active agent pellets or granules.
- FIG. 5 illustrates an overview of one embodiment of granulation and tabletting processes.
- FIG. 6 illustrates a relationship between the amount of coating in particles versus the mean particle size for one embodiment of the invention.
- FIG. 7 illustrates the effect of coating amount applied on drug release from the coated particles.
- FIG. 10 illustrates release profiles from two different shaped 606 mg tablets composed of 100% Surelease® coated particles in PEO/PEG matrix prepared by fluid-bed granulation (HPLC method).
- FIG. 11 illustrates dissolution profiles of tablets comprising SR pellets in the core of the tablet.
- a sustained release tablet refers to a tablet which is capable of releasing an active agent to the body for a prolonged period of time, e.g., for at least about 8 hours, preferably for at least about 12 hours, more preferably for at least about 16 hours, and most preferably for up to about 18-24 hours.
- a sustained release tablet releases the active agent from the tablet gradually into the body.
- a sustained release tablet that is designed to release of the active agent for about 18-24 hours preferably has the following dissolution specification using the dissolution test method described in Example 6A: no more than 40% of the active agent (e.g., by weight) released in 1 hour, about 70-85% of the active agent released in 12 hours, and no less than about 80% of the active agent released at 24 hours.
- a sustained release tablet is designed to release the active agent at a nearly linear zero order rate (typically when the active agent dissolution is measured up to 70% of the active agent release).
- the “size” of active granules or pellets, or coated beads or coated particles refers to the average dimension and can be measured by either laser diffraction sizer analysis or mechanical siever such as Ro-Tap.
- a range of “molecular weight” of a polymer (e.g., a polyethylene oxide polymer) or a gelation facilitator agent (e.g., a polyethylene glycol) described below is a weighted average molecular weight (measured by gel permeation chromatography).
- Tablet “hardness” is physical strength measurement of the tablet. The resistance of a tablet to chipping, abrasion, or breakage under conditions of storage, transportation and handling before usage depends on its hardness, or “crushing strength.”
- the tablet “crushing” or “tensile” strength is defined as the force required to break a tablet by compression in the radial direction. It is typically measured using one of the many commonly available tablet hardness testers. For example, “Stokes” and “Monsanto” hardness testers measure the force required to break the tablet when the force generated by a coil spring is applied diametrically to the tablet.
- a “Strong-Cobb” hardness tester also measures the diametrically applied force required to break a tablet, the force applied by an air pump forcing a plunger against the tablet placed on an anvil.
- Electrically operated hardness testers such as the Schleuniger apparatus (also known as a “Heberlein”) can be used. See also, TS-50N, Okada Seiko Co., Japan; Bi (1996) Chem. Pharm. Bull . ( Tokyo ) 44:2121-2127.
- the tablet hardness can be represented by various units, including in the units of kilopounds (“kp”).
- the “gelation index” or “percent gelation” as used herein represents the percentage of the portion of the tablet which has undergone gelation.
- the method of calculating the gelation index is not particularly limited but the following calculation method may be mentioned as an example.
- JP The Pharmacopeia of Japan XII
- Disintegration Test Fluid 2 a gelation test can be carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm.
- the test tablet is moistened for a predetermined time.
- the test tablets are then taken out at predetermined intervals, the gel layer is removed and the diameter (D obs) of the portion not forming a gel can be measured.
- D obs The diameter of the portion not gelled after initiation of test
- the invention provides a modified tablet comprising a gel-forming material and at least one particle comprising an active agent, wherein the particle is formulated to modify release of the active agent from the tablet (e.g., the active agent in contact with a coating material).
- the gel-forming material forms a matrix (i.e., a gel-forming matrix) for the active agent-containing particles in the modified tablet.
- the particle comprises an active agent and a coating material on or around the active agent, wherein the coating material modifies the release of the active agent from the tablet.
- the combination of the gel-forming matrix and the particle comprising a coating material can provide any desired active agent release profile.
- embodiments of the invention can provide a sustained release of a hydrophilic drug from the tablet for at least 8 hours, preferably up to between about 12-24 hours.
- these tablets typically comprise components that are physiologically or pharmacologically acceptable.
- the gel-forming material may comprise: (1) a polymer; and (2) a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C.
- the polymer is water insoluble and contributes to forming a network of materials within the matrix which can swell upon absorbing water.
- the gelation facilitator agent is a hydrophilic base that draws water into the core of the gel-forming matrix of the tablet, thereby allowing a substantially complete gelation of the entire tablet before the tablet reaches the large intestine.
- Different forms and/or types of the polymers and the gelation facilitator agent can be used to modify the gelation rate and/or erosion rate of the gel matrix. They can be selected to provide a controlled release pattern of the active agent-containing particles. Other additives can be incorporated to further modify the gelation and/or release pattern of the active agent.
- the particle is formulated to further modify the release of the active agent (in particular the hydrophilic agent) from the tablet.
- the particle comprises an active agent and a coating material on, and preferably around, the active agent.
- the active agent can be in any suitable form.
- the active agent can be in the form of a crystal, a granule, or a pellet. These active agent forms may facilitate certain coating processes of the active agents.
- the particle can comprise a single active agent crystal (or granule or pellets) or can comprise a plurality of active agent crystals (or granules or pellets).
- the tablets are designed to have pulsatile or delayed onset release profiles. This can be achieved by designing, e.g., a multilayered tablet. Different layers of the multilayered tablet can have different active agents, different amounts of active agents, different forms of active agents, different amounts or kinds of coating materials, different amounts or kinds of gel-forming materials, etc.
- active agent-containing particles can be distributed randomly (see, e.g., FIG. 1A) or can be distributed non-randomly (see, e.g., FIGS. 2 A- 2 C).
- FIG. 1A illustrates one of many examples of the modified tablet according to an embodiment of the invention.
- Tablet 101 comprises a plurality of active agent-containing particles 11 and a gel-forming material 10 surrounding the particles. Additional details regarding the active agents and gel-forming materials are described below.
- FIG. 1B illustrates an enlarged view of an active agent-containing particle 11 ( a ).
- Particle 11 ( a ) comprises an active agent 12 ( a ) as a core element and a coating material 13 ( a ) on and around the active agent 12 ( a ).
- FIG. 1C illustrates an enlarged view of another example of another active agent-containing particle 11 ( 1 b ).
- Particle 11 ( 1 b ) comprises a plurality of active agents 12 ( b ) and a coating material 13 ( b ) on and around the plurality of active agents 12 ( b ).
- Particle 11 ( b ) also comprises a plurality of active agents 12 ( c ) and a coating material 13 ( b ) on, but not necessary around all of the active agents 12 ( c ).
- the plurality of active agents 12 ( b ) and 12 ( c ) can be dispersed throughout the coating material 13 ( b ).
- FIG. 2A illustrates another example of a tablet according to an embodiment of the invention.
- Tablet 102 comprises a plurality of different types of particles 11 , 16 and 17 in the gel-forming matrix 10 .
- Each particle may have the same or different form.
- the particles 11 , 16 and 17 can have the form of either of the previously described particles 11 ( a ) or 11 ( b ).
- Particles 11 , 16 and 17 can comprise the same active agent but can be differently formulated to have different release properties (e.g., different amounts or different types of coating material).
- particles 11 , 16 and 17 can comprise different types of active agents.
- the particles 11 near the outer surface of the tablet 102 can be suitable for release into the upper digestive tract, while the particles 16 and 17 in the inner region of the tablet 102 can be suitable for release into the lower digestive tract.
- particles 11 , 16 and 17 can comprise different amounts or types of active agents or different amounts or types of coating material on them. These particles 11 , 16 and 17 can be distributed randomly or can be distributed non-randomly in the tablets.
- FIG. 2B illustrates another example of the tablets according to an embodiment of the invention.
- Tablet 103 is a multilayered tablet, wherein the core portion 10 comprises particles 11 and the outer portion 15 is devoid of particles.
- Each portion can comprise different types of gel-forming material to further control the release of the particles comprising an active agent.
- This type of tablet is particularly useful to delay the onset of release of the active agent from the tablet 103 .
- the outer portion 15 can erode as the tablet passes through the upper digestive tract. When the tablet reaches the colon, the outer portion has eroded away and erosion of the gel-forming material of the core portion can begin, resulting in the release of the active agent-containing particles into the colon.
- FIG. 2C illustrates yet another example of a tablet according to an embodiment of the invention.
- the tablet 104 comprises three layers.
- the core portion 10 comprises active agent-containing particles 11
- the intermediate portion 14 comprises active agent-containing particles 16
- the outer portion 18 is devoid of particles.
- Particles 11 and 16 can be modified to have different release properties.
- the particles 11 and 16 can have different amounts or different types of coating material.
- the particles 11 and 16 can also comprise different types of active agents.
- Each portion 11 , 14 and 18 of the tablet may comprise different amounts or types of gel-forming materials to further control the release of the particles from the tablet.
- Embodiments of the invention shown in FIGS. 1 and 2 are merely illustrative, and other variations are readily determinable by those skilled in the art.
- embodiments of the tablet can further include untreated active agents (e.g., without coating material or in powders) in addition to active agent-containing particles.
- the active agent is a drug.
- the active agent is not necessarily limited to a drug, but can be a nutritional additive (e.g., vitamin), a placebo, or a reagent (e.g., a diagnostic reagent, a radioimaging reagent, or a magnetic imaging reagent).
- the active agent is hydrophilic and has a water solubility of at least about 30 mg/ml at a temperature of about 25° C.
- a hydrophilic active agent has a water solubility of at least about 50 mg/ml, at least about 100 mg/ml, at least about 200 mg/ml, at least about 300 mg/ml, at least about 400 mg/ml, at least about 500 mg/ml, at least about 600 mg/ml, at least about 700 mg/ml, at least about 800 mg/ml, at least about 900 mg/ml, at least about 1,000 mg/ml, at least about 1,200 mg/ml, or at least about 1,500 mg/ml at a temperature of about 25° C.
- hydrophilic active agent examples include, cevimeline HCl, pseudoephedrin HCl, pyrilamine maleate, phenmetrazine HCl, hyoscyamine sulfate, edophonium HCl, doxylamine succinate, hydroxyzine HCl, fluphenazune HCl, niacinamide, etc.
- the active ingredient of the tablet is (+/ ⁇ )-cis-2-methylspiro [1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate; also known as SNI-2011, cevimeline hydrochloride, AF102B, SND-5008, and FKS-508.
- SNI-2011 is a rigid analogue of acetylcholine. See, e.g., Iga (1998) Jpn. J. Pharmacol. 78:373-380; Iwabuchi (1994) Arch. Int. Pharmacodyn. Ther. 328(3):315-25.
- SNI-2011 and analogues are highly water soluble drugs, having a water solubility of about 1,400 mg/ml at 25° C.
- Cevimeline hydrochloride has a water solubility of 766 mg/ml at 25° C. They specifically bind to specific muscarinic receptors in various exocrine glands. They have demonstrated beneficial effects on xerostomia and keratoconjunctivitis sicca in patients with Sjogren's syndrome, see, e.g., Iwabuchi (1994) Gen. Pharmacol. 25:123-129.
- the daily dose of these and other drugs that can achieve 18-24 hour extended release is incorporated into the tablet.
- This dosage could accommodate once a day dosing of the active agent.
- the weight percent of the active agent itself can be between about 0.5% to about 50% of the total tablet weight.
- an active agent can be non-hydrophilic (e.g., hydrophobic) or can have a water solubility of less than, e.g., 30 mg/ml or 20 mg/ml at a temperature of about 25° C.
- an active agent is a drug that is unstable if it is in contact with water or a gel-forming matrix for a prolonged period of time (e.g., sensitive to moisture or oxidation).
- active agents may benefit by having a physical and/or chemical barrier (e.g., a coating material) on or around the active agents.
- unstable drugs include antibiotic drugs such as efrotomycin, milbemycins, tylosin derivatives, avermectins, ivermectin, mocimycin, goldinomycin, and the like.
- the active agents include, but are not limited to, e.g., anti-inflammatory, antipyretic, anticonvulsant and/or analgesic agents such as indomethacin, diclofenac, diclofenac Na, codeine, ibuprofen, phenylbutazone, oxyphenbutazone, mepirizol, aspirin, ethenzamide, acetaminophen, aminopyrine, phenacetin, scopolamine butylbromide, morphine, etomidoline, pentazocine, fenoprofen calcium, etc; tuberculostats such as isoniazid, ethambutol hydrochloride, etc.; cardiocirculatory system drugs such as isosorbide dinitrate, nitroglycerin, nifedipine, barnidipine hydrochloride, nicardipine hydroch
- analgesic agents such as indomethacin, diclofenac,
- Typical drugs among the above drugs is nicardipine hydrochloride, SNI-2011, nifedipine, ditilazem hydrochloride, phenylpropanolamine hydrochloride, indomethacin, potassium hydrochloride, diazepamtheophylline, verapamil, morphine, and the like.
- the active agent can be in any suitable form.
- it can be in the form of a particle, powder, a crystal, a granule (i.e., an aggregate of smaller units of active agent, also referred to as a pellet).
- the active agents may be used as purchased (in the form of a powder or a crystal) or may be processed to form active agent granules or pellets.
- active agent granules or pellets are spray coated with a coating material to form coated active agent-containing particles, the active agents are preferably granulated or pelletized to improve the chemical or physical characteristics of the active agents for coating processes.
- it may be preferable that active agents are in the form of a granule or a pellet that has relatively high density and hardness, and relatively low brittleness and surface area.
- An active agent can be pelletized or granulated using any suitable methods known in the art. Pelletization or granulation is commonly defined as a size-enlargement process in which small particles are gathered into larger, permanent aggregates in which the original particles can still be identified.
- FIG. 3 illustrates one of many examples of an overview of pelletization or granulation development with one embodiment of the active agent (i.e., Cevimeline HCl). Prior to granulation, a binder can be added to the active agent to improve the granulation process.
- the active agent i.e., Cevimeline HCl
- a suitable binder examples include, hydroxypropyl cellulose (HPC), a mixture of polyethylene oxide and polyethylene glycol, acacia, carbomer, carboxymethylcellulose sodium, ethylcellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl methylcellulose, maltodextrin, povidone, pregelatinized starch, zein, starch, and the like.
- HPC hydroxypropyl cellulose
- Other additives can be added during granulation. These include, e.g., sweeteners, flavors, color agents, antioxidants, etc.
- water or other solvent can be added to aid the granulation process.
- the amount of water or solvent added depends on, e.g., the selection of a granulation process, and is readily determinable by those of skill in the art.
- Water or other solvent may be added at any suitable time point during the granulation process.
- a binder may be mixed with a solvent (e.g., water) to form a binder solution, and then the binder solution can be sprayed onto active agents.
- a binder solution is too viscous to be uniformly sprayed onto active agents, it may be desirable to blend the binder with the active agent first and then spray water or other solvent to produce uniform pattern of active agent granules or pellets.
- Any suitable granulation methods can be used to produce particles comprising an active agent.
- granulation is any process of size enlargement whereby small particles are gathered together into larger, permanent aggregates to render them into a free-flowing state.
- wet granulation or dry granulation methods can be used.
- Dry granulation refers to the granulation of a formulation without the use of heat and solvent.
- Dry granulation technology generally includes slugging or roll compaction. Slugging consists of dry-blending a formulation and compressing the formulation into a large tablet or slugs on a compressing machine. The resulting tablets or slugs are milled to yield the granules. Roller compaction is similar to slugging, but in roller compaction, a roller compactor is used instead of the tableting machines. See, e.g., Handbook of Pharmaceutical Granulation Technology , D. M. Parikh, eds., Marcel-Dekker, Inc. pages 102-103 (1997). Dry granulation technique is useful in certain instances, e.g., when the active agent is sensitive to heat or solvent.
- wet granulation can be used.
- solvents and binders are typically added to a formulation to provide larger aggregates of granules.
- the temperature during granulation can be set at any suitable point, generally not exceeding the melting point of any components of the formulation.
- the mixture is granulated at a temperature of about 35° C. to about 65° C. for about 20 to 90 minutes. Then the granules are typically air dried for a suitable duration (e.g., one or more hours).
- the active agents are granulated with high shear mixer granulation (“HSG”) or fluid-bed granulation (“FBG”). Both of these granulation processes provide enlarged granules or pellets but differ in the apparatuses used and the mechanism of the process operation.
- HSG high shear mixer granulation
- FBG fluid-bed granulation
- blending and wet massing is accomplished by high mechanical agitation by an impeller and a chopper. Mixing, densification, and agglomeration of wetted materials are achieved through shearing and compaction forces exerted by the impeller.
- the primary function of the chopper is to cut lumps into smaller fragments and aid the distribution of the liquid binder.
- the liquid binder is either poured into the bowl or sprayed onto the powder to achieve a more homogeneous liquid distribution.
- fluidization is the operation by which fine solids are transformed into a fluid-like state through contact with a gas. At certain gas velocities, the fluid will support the particles, giving them freedom of mobility without entrainment. Such a fluidized bed resembles a vigorously boiling fluid, with solid particles undergoing extremely turbulent motion, which increases with gas velocity. Fluidized bed granulation is then a process by which granules are produced in fluidized bed by spraying a binder solution onto a fluidized powder bed to form larger granules.
- the binder solution can be sprayed from, e.g., a spray gun positioned at any suitable manner (e.g., top or bottom). The spray position and the rate of spray may depend on the nature of the active agent and the binder used, and are readily determinable by those skilled in the art.
- HSG can be performed using Aeromatic-Field GP1/SP General Processor.
- the HSG process is preferred. For example, when Cevimeline HCl was granulated using either HSG or FBG processes, it was found that the HSG process generated the Cevimeline HCl granules or particles of higher density than the FBG process.
- granulated active agents can be milled. Milling can be performed using any commercially available apparatuses (e.g., Comil equipped with a 0.039 inch screen).
- the mesh size for the screen can be selected depending on the size of the active agent granule or pellet desired. Typically, the mesh size can range from 0.331 inch screen (mesh 20) to 0.006 inch screen (mesh 100). The milling process aids in providing relatively uniform active agent granules. After the granulated active agents are milled, they may be further dried (e.g., in the air) if desired.
- the mean size of the active agent granule or pellet can range from about 50 ⁇ m to about 3 mm, optionally about 100 ⁇ m to about 2 mm, or optionally about 300 ⁇ m to about 1 mm.
- the bulk density or the tap density of the active agent granules or pellets range from about 0.1 g/ml to about 1.5 g/ml, optionally about 0.3 g/ml to about 0.8 g/ml, optionally about 0.4 g/ml to about 0.6 g/ml. Bulk density is measured based on USP method (see US Pharmacopoeia , edition XXIV, pages 1913-1914, testing method ⁇ 616>, incorporated herein by reference).
- Active agents are processed to form a particle with a coating material, wherein the coating material is in contact with the active agents to modify the release of the active agents.
- the particle comprises an active agent and a coating material on or around the active agent as shown in FIG. 1B or 1 C.
- this physical/chemical modification of the active agent provides improved sustained or controlled release of active agents from the tablet.
- the coating material can be a natural polymer, a semi-synthetic polymer, or a synthetic polymer. These include, but are not limited to, chitosan, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, cellulose acetate membrane, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyacrylic acid, polyvinyl acetate, poly(vinylacetate phthalate), poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(lactic acid), poly(glycolic acid), poly(lactic/glycolic acid), poly(dimethyl silicone), poly(hydroxyethyl methacrylate), poly(ethylene/vinyl acetate), poly(ethylene/vinyl acetate), poly(ethylene/vinyl acetate), poly(ethylene/viny
- the coating material is less hydrophilic than the active agent so that the coating material inhibits the diffusion of the hydrophilic active agent through the tablet.
- a water insoluble or hydrophobic coating material can be used.
- examples of a hydrophobic coating material include ethyl cellulose, polymethacrylic polymers, polyvinylacetate, cellulose acetate polymers, etc.
- the coating material is flexible so that it is flexible to withstand the compression pressure during the production of compressed tablets.
- a tablet is generally compressed to a hardness of at least about 2 kp, typically between about 2 kp to about 10 kp.
- the coating material preferably comprises sufficient flexibility, plasticity, or elasticity so that it does not deform (e.g., crack or break) during the tablet compression of at least about 2 kp.
- a plasticizer may be included in the coating material to increase the flexibility of the coating material. Examples of a plasticizer include benzyl benzoate, chlorobutanol, dibutyl sebacate, diethyl phthalate, clycerin, mineral oil, polyethylene glycol, sorbitol, triacetin, triethyl citrate, etc.
- a stabilizer such as acacia, bentonite, cyclodextrins, glyceryl monostearate, propylene glycol, white or yellow wax, Xanthan gum, etc.
- a stabilizer such as acacia, bentonite, cyclodextrins, glyceryl monostearate, propylene glycol, white or yellow wax, Xanthan gum, etc.
- a stabilizer such as acacia, bentonite, cyclodextrins, glyceryl monostearate, propylene glycol, white or yellow wax, Xanthan gum, etc.
- these coating materials are in the form of an aqueous polymeric dispersion and are commercially available.
- these include Surelease® (ethyl cellulose), EudragitTM RS/NE (polyacrylic polmers) and Kollicoat® SR (polyvinylacetate), etc.
- these commercially available coating materials include a plasticizer and/or a stabilizer.
- a single active agent crystal or granule or a plurality of active agent crystals or granules can be coated to form a single particle.
- the particle 11 ( a ) may comprise a single active agent crystal or granule 12 ( a ) and coating material 13 ( a ) on and around the active agent. These particles can be produced by, e.g., spraying a coating material on an individual active agent crystal or granule.
- the particle 11 ( b ) may comprise a plurality of active agents (powders, crystals, or granules) 12 ( b ) and 12 ( c ) and coating material 13 ( b ) on or around the active agents.
- Particles as shown in FIG. 1C can be produced by, e.g., applying the coating material on the active agent powder, crystals or pellets and then chopping (and optionally milling) the coated mixture into particles.
- the particles comprising the active agent and the coating materials are herein also referred to as beads or coated beads or coated particles.
- Any suitable coating methods can be used to produce particles comprising an active agent and a coating material on or around the active agent.
- a type A or a type B coating or encapsulation process can be used.
- Type A processes include simple or complex coacervation, interfacial polymerization in liquid media, in-liquid drying, thermal and ionic gelation in liquid media, or desolvation in liquid media techniques.
- a coacervation process can be used.
- the water phase is utilized as the continuous phase (see, e.g., Ertan (1997) J. Microencapsul. 14:379-388; Tuncel (1996) Pharmazie 51:168-171).
- water soluble polymers can be used in the coacervation process.
- Typical coating or microencapsulating polymers include, e.g., polyamides, polyesters, polyurethanes, and the polyureas and the like.
- the interfacial polymerization process can be used.
- two polymeric monomer suspensions are used—a discontinuous phase comprising particles comprising active agents to be encapsulated and a continuous phase for coating films.
- the two monomers react at the interface between the core and the continuous phase, causing polymerization under controlled process conditions.
- a phase separation technique can be used (see, e.g., Mandal (1998) Drug Dev. Ind. Pharm. 24:623-629).
- a polymer of discontinuous phase is generally phased out or desolvated from the solvent continuous phase.
- This polymer of discontinuous phase will deposit around a reservoir such as a liquid droplet or a solid particle as a polymer wall.
- the polymer can be deposited either by temperature differential, by the introduction of a second polymer, or by the evaporation of the solvent.
- Type B processes utilize spray drying, spray chilling, fluidized bed coating, spray drying, pan coating, and spray coating, electrostatic deposition, centrifugal extrusion, spinning disk or rotational suspension separation, polymerization at liquid-gas or solid-gas interface, pressure extrusion or spraying into solvent extraction bath techniques.
- Pan coating can be utilized for multiple layer coatings of the tablet (see, e.g., Heinamaki (1997) Pharm. Dev. Technol. 2:357-364).
- Fluid bed coating, referred to as Wurster coating, and spray drying techniques can also be utilized for coating the active agent (see, e.g., Jono (1999) Chem. Pharm. Bull . (Tokyo) 47:54-63; Miyamoto (1997) Chem. Pharm. Bull . (Tokyo) 45:2043-2050).
- the selection of a suitable coating process depends on the physical and chemical characteristics of the active agent, the coating material, etc. and is determinable by those skilled in the art. For instance, when a spray system is used to coat the active agents, it may be desirable to use a coating material that does not have a high tack in its formula which could lead to clogging of the nozzle of the spray system.
- any suitable amount of coating material can be applied on the active agent as long as the coating provides sufficient diffusion or protective barrier for the active agent.
- about 20% to about 150% of the coating is applied to the active agent granule, wherein the % coating means % ratio (w/w) of the amount of coating polymer used to the amount of active agent granule (and a binder and other materials in the granule).
- the % coating means % ratio (w/w) of the amount of coating polymer used to the amount of active agent granule (and a binder and other materials in the granule).
- about 30% to about 80% of coating is applied. More preferably, about 40% to about 60% of coating is applied.
- the mean size of the particles can range, e.g., from about 50 ⁇ m to about 5 mm, optionally about 100 ⁇ m to about 3 mm, or optionally about 300 ⁇ m to about 2 mm.
- the bulk density or the tap density of these particles are slightly higher than uncoated active agent granules or pellets.
- the bulk density or the tap density of the particles can range from about 0.1 g/ml to about 5 g/ml, optionally about 0.3 to about 3 g/ml, optionally about 0.5 g/ml to about 1.0 g/ml.
- the particles are round, even, and smooth.
- the particles are relatively strong and yet flexible.
- any suitable amount of active agent-containing particles can be included into the final formulation. Typically, about 5% to about 60% of active agent-containing particles by weight to the total weight of the tablet are included. The selection of a suitable amount of active agent-containing particles depends on the dosage desired and is readily determinable by those skilled in the art.
- the active agent-containing particles are then blended with a gel-forming material, and the final blend is compressed into tablets without damaging the particles.
- the gel-forming material forms a matrix for the particles and comprises a polymer and a gelation facilitator agent.
- the polymer provides a structural basis for the matrix of the tablet to swell upon absorbing water.
- the gelation facilitator agent is a hydrophilic base that draws water into the core of the gel-forming matrix, thereby allowing substantially gelation of the entire tablet.
- the gel-forming matrix absorbs water to undergo substantially complete gelation during its stay in the upper digestive tract and moves into the lower digestive tract undergoing constant erosion, continuously releasing the active agent-containing particles.
- the polymer in the gel-forming matrix has physical characteristics, inclusive of viscosity in the gelled state, which permits the tablet to retain its shape more or less during its travel down to the lower digestive tract, including the colon, withstanding the contractile forces of the digestive tract associated with the digestion of food.
- the properties of the polymer depends on its molecular weight, viscosity, etc.
- the polymer used in the present invention typically has an average molecular weight ranging from about 0.5 ⁇ 10 6 daltons to 10 ⁇ 10 6 daltons, more typically ranging from 1 ⁇ 10 6 daltons to 8 ⁇ 10 6 daltons.
- the polymer component in the gel-forming material has an average molecular weight of at least about 1 ⁇ 10 6 daltons and has a viscosity of at least about 1,000 cps in a 1% water solution at a temperature of about 25° C. (i.e., if 1% by weight of PEO is added to water, the aqueous solution containing PEO has a viscosity of at least about 1,000 cps). More preferably, the polymer has an average molecular weight of at least about 2 ⁇ 10 6 daltons, even more preferably between about 5 ⁇ 10 6 daltons to about 10 ⁇ 10 6 daltons. If desired, any mixture of two or more polymers can be used included in the gel-forming material.
- polyethylene oxide e.g., Polyox WRS-303 (average mol. wt.: 7 ⁇ 10 6 ; viscosity: 7500-10000 cps, 1% in H 2 O, 25° C.), Polyox WSR Coagulant (average mol. wt.: 5 ⁇ 10 6 ; viscosity: 5500-7500 cps, under the same condition above), Polyox WSR-301 (average mol. wt.: 4 ⁇ 10 6 viscosity: 1650-5500 cps, under the same condition above), Polyox WSR-N-60K (average mol.
- PEO polyethylene oxide
- Polyox WRS-303 average mol. wt.: 7 ⁇ 10 6 ; viscosity: 7500-10000 cps, 1% in H 2 O, 25° C.
- Polyox WSR Coagulant average mol. wt.: 5 ⁇ 10 6 ; viscosity: 5500-7500 cps,
- wt. 2 ⁇ 10 6 ; viscosity: 2000-4000 cps, 2% in H 2 O, 25° C.), all of which are trade names of Union Carbide Co.]; hydroxypropylmethylcellulose (HPMC) [e.g., Metolose 90SH10000 (viscosity: 4100-5600 cps., 1% in H 2 O, 20° C.), Metolose 90SH50000 (viscosity: 2900-3900 cps, under the same condition above), Metolose 90SH30000 (viscosity: 25000-35000 cps, 2% in H 2 O, 20° C.), all of which are trade names of Shin-Etsu Chemicals Co.]; sodium carboxymethylcellulose (CMC-Na) [e.g., Sanlose F-150MC (average mol.
- CMC-Na sodium carboxymethylcellulose
- HEC Daicel SE900 average mol. wt.: 156 ⁇ 10 4 ; viscosity: 4000-5000 cps, under the same condition above, all of which are trade names of Daicel Chemical Industries]; carbonxyvinyl polymers [e.g., Carbopol 940 (average mol. wt.: ca. 25 ⁇ 10 5 ; B. F. Goodrich Chemical Co.) and so on.
- a PEO is used as a polymer as part of the gel-forming material.
- a polymer having a higher molecular weight preferably an average molecular weight of more than 4 ⁇ 10 6 daltons, or a higher viscosity, preferably a viscosity of more than 3000 cps at a concentration of 1% in water at 25° C., is preferable.
- the gelation facilitator agent can be at least one excipient having solubility higher than 0.1 g/ml in water at room temperature (e.g., 20° C.).
- the gelation facilitator agent allows water to penetrate into the core of the tablet. The higher the solubility of the gelation facilitator agent in water, the more effective it is in allowing into the core of the tablet.
- the gelation facilitator agent has water solubility of at least about 0.2 g/ml, more preferably at least about 0.25 g/ml, most preferably at least about 0.3 g/ml at room temperature (e.g., 20° C.).
- gelation facilitator agent examples include highly hydrophilic polymers such as different molecular weight polyethylene glycol (PEG), e.g., polyethylene glycols (PEG), e.g. PEG400, PEG800, PEG100, PEG1200, PEG1500, PEG2000, PEG4000, PEG6000, PEG8000, PEG10000 and PEG20000, and the like (produced by, e.g., Nippon Oils and Fats Co.), or mixtures thereof.
- PEG polyethylene glycol
- PEG400 polyethylene glycols
- PEG800 polyethylene glycols
- PEG100 polyethylene glycols
- PEG1200 polyethylene glycols
- PEG1500 e.g. PEG1500
- PEG2000, PEG4000, PEG6000, PEG8000, PEG10000 and PEG20000 e.g., Nippon Oils and Fats Co.
- Other highly hydrophilic polymers that can be used as gelation facilitator agents include polyvin
- HCO polyoxyethylene-hydrogenated castor oil
- Cremophor RH40TM produced by BASF, HCO-40TM and HCO-60TM produced by Nikko Chemicals Co.
- polyoxyethylene-polyoxypropylene glycol e.g.
- Pluronic F68TM produced by Ashai Denka Kogyo K.K.
- polyoxyethylene-sorbitan fatty acid ester Teween; e.g. Tween 80 produced by Knato Kagaku K.K.
- salts such as sodium chloride, magnesium chloride, etc.
- organic acids such as citric acid, tartaric acid, etc.
- amino acids as glycine, ⁇ -alanine, lysine hydrochloride, etc.
- amino sugars such as meglumine.
- a PEG is used as a gelation facilitator agent.
- a PEG used in the embodiments of the invention has an average molecular weight between about 4 ⁇ 10 2 daltons and about 2 ⁇ 10 4 daltons.
- a PEG having an average molecular weight between about 400 daltons to about 1500 daltons is used.
- the formulation contains about 5 to about 85 weight %, preferably about 20 to about 70 weight %, and more preferably about 40 to about 60 weight % of the gel-forming material (e.g., the polymer and the gelation facilitator agent combined) based on the total weight of the preparation. If the amount of this polymer is less than the above-mentioned level, the preparation may not tolerate erosion in the digestive tract and may not achieve a sustained release of the active agent.
- the proportion of the gelation facilitator agent to the polymer depends on the characteristics of the active agent (solubility, therapeutic efficacy, etc.) and content of the active agent, solubility of the gelation facilitator agent itself, characteristics of the polymer used, the patient's condition at the time of administration and other factors. For administration to human patients, however, the proportion of the polymer to the gelation facilitator agent is such that the tablet can achieve a substantially complete gelation in about 4 to 5 hours after administration.
- the amount of the gelation facilitator agent in the tablet is such that the tablet can achieve at least about 70%, preferably at least about 80% gelation or gelation index after two hours according to the gelation test provided in the definition section above (see, also, EP 0 661 045 A1, incorporated herein by reference).
- the content of the gelation facilitator agent is too small, the necessary gelation into the core of the preparation does not proceed so that the release of the active agent in the colon becomes insufficient.
- the content of the gelation facilitator agent is excessive, the gelation proceeds in a shorter time but the resulting gel becomes so fragile that the release of the active agent is too fast, thus failing to insure a sufficient sustained release.
- the ratios of the polymer to gelation facilitator agent are, therefore, generally between about 0.1:99.9 to about 99.9 to 0.1; between about 1:99 to about 99:1 by weight; between about 1:9 to about 9:1 by weight; between about 3:7 to about 7:3 by weight; between about 4:6 to about 6:4 by weight; or between about 3:4 to about 4:3 by weight.
- a slower rate of active agent release can be observed.
- polymers such as hydroxypropylmethylcellulose (HPMC), sodium carboxymethylcellulose (CMC-Na), hydroxyethylcellulose (HEC), carboxyvinyl polymers and the like can be added to the tablet formulation to adjust and thus program the release pattern of the active agent.
- HPMC hydroxypropylmethylcellulose
- CMC-Na sodium carboxymethylcellulose
- HEC hydroxyethylcellulose
- carboxyvinyl polymers and the like can be added to the tablet formulation to adjust and thus program the release pattern of the active agent.
- the preparation of the present invention may include appropriate amounts of other pharmaceutically acceptable additives such as vehicles (e.g., lactose, mannitol, potato starch, wheat starch, rice starch, corn starch, and crystalline cellulose), binders (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, and gum arabic), swelling agents (e.g., carboxymethylcellulose and carboxy-methylcellulose calcium), lubricants (e.g., stearic acid, calcium stearate, magnesium stearate, talc, magnesium meta-silicate aluminate, calcium hydrogen phosphate, and anhydrous calcium hydrogen phosphate), fluidizers (e.g., hydrous silica, light anhydrous silicic acid, and dried aluminum hydroxide gel), colorants (e.g., yellow iron sesquioxide and iron sesquioxide), surfactants (e.g., sodium lauryl sulfate, sucrose fatty acids), binders (
- any suitable methods can be used to mix the formulation comprising the active agent-containing particles and the gel-forming materials (e.g., the polymer and the gelation facilitator). For example, direct compression or granulation (wet or dry) methods can be used.
- the active agent-containing particles and the gel-forming materials are combined, and the mixture may be directly compressed into a tablet.
- one or more vehicles or additives may be added to the mixture to improve flow and compressible characteristics.
- additives include, for example, lubricants, such as magnesium stearate, zinc stearate, stearic acid, talc and the like, flavors, or sweeteners.
- Direct compression has advantages, such as reducing cost, time, operational pace and machinery; preventing active agent-excipient interaction and less instability of active agent. Direct blending or slugging can also eliminate the possible pollution by organic solvent.
- a wet granulation process can be used to mix one or more components of the formulation.
- high shear granulation or fluid-bed granulation processes can be used. Any suitable commercially available granulation apparatuses can be used in these processes.
- a dry granulation process can be used to mix one or more components of the formulation.
- slugging or roller compaction can be used. Both wet and dry granulation processes and apparatuses are described in detail above.
- some of the formulation components may be partially granulated prior to compression or all of the formulation components may be granulated prior to compression.
- some or all components of the gel-forming material can be granulated prior to mixing the active agent-containing particles.
- the polymer component (e.g., PEO) of the gel-forming material can be granulated prior to mixing with the gelation facilitator agent and/or with the particles.
- the gelation facilitator agent of the gel-forming material can be granulated prior to mixing with the polymer and/or the particles.
- the particles comprising an active agent can be granulated together with the gel-forming material (e.g., the polymer, the gelation facilitator agent, or both). If any of the gel-forming material is granulated first, preferably, the granules of the gel-forming material are soft or flexible enough not to damage the active agent-containing particles during compression.
- the gel-forming material e.g., the polymer, the gelation facilitator agent, or both.
- granulated formulation can be milled. Milling can be performed using any suitable commercially available apparatus (e.g., Comil equipped with a 0.039 inch screen). The mesh size for the screen can be selected depending on the size of the granules desired. After the granulated active agents are milled, they may be further dried (e.g., in the air) if desired.
- the formulation is compressed into a tablet form.
- This tablet shaping can be done by any suitable means, with or without compressive force.
- compression of the formulation after the granulation step can be accomplished using any tablet press, provided that the tablet composition is adequately lubricated.
- the level of lubricant in the formulation is typically in the range of 0.5-2.0%, with magnesium stearate which is most commonly used as a lubricant.
- Other lubricants such as zinc stearate, stearic acid, talc and the like, may also be used. Many alternative means to effect this step are available, and the invention is not limited by the use of any particular apparatus.
- the compression step can be carried out using a rotary type tablet press.
- the rotary type tableting machine has a rotary board with multiple through-holes, or dies, for forming tablets. The formulation is inserted into the die and is subsequently press-molded.
- the diameter and shape of the tablet depends on the molds, dies and punches selected for the shaping or compression of the granulation composition. Tablets can be discoid, oval, oblong, round, cylindrical, triangular, and the like. The tablets may be scored to facilitate breaking. The top or lower surface can be embossed or debossed with a symbol or letters.
- the compression force can be selected based on the type/model of press, what physical properties are desired for the tablets product (e.g., desired hardness, friability, etc.), the desired tablet appearance and size, and the like.
- the compression force applied is such that the compressed tablets have a hardness of at least about 2 kp. These tablets generally provide sufficient hardness and strength to be packaged, shipped or handled by the user. If desired, a higher compression force can be applied to the tablet to increase the tablet hardness.
- the compression force is preferably selected so that it does not deform (e.g., crack or break) the active agent-containing particles within the tablet.
- the compression force applied is such that the compressed tablet has a hardness of less than about 10 kp. In certain embodiments, it may be preferred to compress a tablet to a hardness of between about 3 kp to about 7 kp, optionally between about 3 kp to about 5 kp, or about 3 kp.
- the final tablet will have a weight of about 100 mg to about 2000 mg, more typically about 200 mg to about 1000 mg, or about 400 mg to about 700 mg.
- modification of active agent release through the tablet matrix of the present invention can also be achieved by any known technique, such as, e.g., application of various coatings, e.g., ion exchange complexes with, e.g., Amberlite IRP-69.
- the tablets of the invention can also include or be coadministered with GI motility-reducing drugs.
- the active agent can also be modified to generate a prodrug by chemical modification of a biologically active compound which will liberate the active compound in vivo by enzymatic or hydrolytic cleavage; etc. Additional layers or coating can act as diffusional barriers to provide additional means to control rate and timing of drug release.
- embodiments of the invention provide tablets that comprise non-randomly (e.g., not evenly) distributed active agent-containing particles
- a non-constant, but controlled level of active agent delivery can be achieved.
- This achieves a “programmable release profile,” such as, e.g., a pulsatile or delayed onset release profile.
- the tablets can also be designed and manufactured such that “lag times” of release are incorporated into this scheme.
- the tablets can be designed to have a delayed onset release of about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, or about 7 hours, after the administration.
- the non-random active agent-containing distribution is controlled through a multilayer tablet formulation design and manufacturing process.
- the non-random distribution of active agent can be represented quantitatively by different amounts in different layers or qualitatively by having different forms of active agent in different layers, e.g., as having more coating materials in the particle in the outer layers as compared to the inner layers of the tablet, or, vice versa.
- alternative layers can have, in addition to varying amounts of active agent, particles comprising the same active agent by different amounts of coating materials or different compositions of coating materials, and the like, or varying amounts of any combination of these alternative forms.
- the non-random distribution of the active agent in the tablet is concentrated at the core of the tablet or is concentrated at the periphery of the tablet.
- the tablet has multiple layers comprising varying amount of active agent or other formulation ingredients. Varying amounts of active agent can be in different layers of the multilayered tablet, e.g., increasing amounts of active agent in the outer layers as compared to the inner layers, or vice versa.
- different forms of active agent e.g., encapsulated, granulated, conjugated
- Completely different types of active agents (e.g., drugs) or combinations thereof can be placed into different layers.
- the layers can be of varying thickness.
- one tablet can have one, two, three, four, fix, six, seven, eight, nine, ten, or any number of layers, limited only by the desired size of the finished tablet product, the thickness of each layer, the composition of each layer's formulation, the manufacturing process, and the like.
- pulsatile release profiles can be designed by varying the rate at which the tablet dissolves as it passes through the digestive tract. This can be accomplished by manufacturing different layers of the multilayered tablet with different kinds or amounts of polymer, e.g., polymer molecular weights, different polymer to gelation facilitator agent ratios, different manufacturing compression forces, and the like.
- polymer e.g., polymer molecular weights, different polymer to gelation facilitator agent ratios, different manufacturing compression forces, and the like.
- the layers themselves can be pre-programmed to dissolve at different rates (and thus release active agent in different anatomical compartments) as the tablet passes through the digestive tract.
- each feeding device emits a defined quantity of material into the female dies as the die travel by the feeding device's output valve.
- Each feeding device has a compressing device directly downstream, as seen in the direction of movement of the female dies. The compressing devices compress the material admitted into the female dies by the respective feeding devices. The compression causes the various layers of material to adhere to one another. Different amount of compressive force can be used for each layer.
- the resulting multilayered compressed tablet is ejected from the female die.
- Any appropriate apparatus for forming multilayer tablets can be used to make the pulsatile release tablets of the invention.
- the tablet can be further processed in any suitable manner, e.g., powder layering in coating pans or rotary coaters; dry coating by double compression technique; tablet coating by film coating technique, and the like. See, e.g., U.S. Pat. No. 5,322,655; Remington 's Pharmaceutical Sciences Handbook : Chapter 90 “Coating of Pharmaceutical Dosage Forms” (1990).
- Cevimeline HCl crystals as received were small and brittle, and were not in an optimal condition to be coated uniformly using the Wurster coating process.
- binders Two different kinds of binders, hydroxypropyl cellulose (HPC) and PEO/PEG, were also tested.
- the choice of the binders was based on the compatibility with the active agent.
- the active agent was pelletized using 10% binder (e.g., HPC) by weight. No other ingredient was added for pelletization.
- the active Cevimeline pellets prepared by the HSG process were coated with coating agents using GPCG-1 (230-VG Versa Glatt, screen size 100 ⁇ ) equipped with Wurster column (diameter 71 mm, partition 1.75 inches).
- GPCG-1 230-VG Versa Glatt, screen size 100 ⁇
- Wurster column diameter 71 mm, partition 1.75 inches.
- FIG. 4 Three different aqueous polymeric dispersions, Surelease® (ethyl cellulose), EudragitTM RS/NE (polyacrylic polymers) and Kollicoat® SR (polyvinylacetate), were examined in terms of the ability of each polymer to form hydrophobic flexible coating membrane. Their formulations were also developed to accommodate effective coating process.
- the following tablets illustrate the formulations developed for the Surelease® and Kollicoat® coating of active agent pellets.
- the formulation is based on using 50% coating.
- This % coating means % ratio of the amount of coating polymer by weight used to the amount of active agent pellets given (including HPC).
- Table 3 500 grams of active pellets were coated with 1008.1 gram of 24.8% dispersion of Surelease® E-7-19010.
- the 50% coating on the active pellets in this example is calculated by multiplying 1008.1 gram by 24.8% (weight of coating polymer), divided by 500 grams (weight of active pellets).
- TABLE 3 Formulation for 50% Surelease ® Coating of 500 g Active Pellets As A Typical Example. Surelease ® E-7-19010* 1008.1 g 20.0%** Coating Polymer (24.8% dispersion) DI-Water 241.9 g 80.0% For Dilution to 20% Total 1250.0 g 100.0%
- Kollicoat ® SR Coating of 500 g Active Pellets As A Typical Example.
- Table 5 illustrates the changes in the physical properties of the Surelease® or Kollicoat® coated active agent-containing particles compared to the physical properites of the active agent pellets without coating (shown in Table 2).
- TABLE 5 Changes (Trend) in the Physical Properties of Active Particles after Surelease ® or Kollicoat ® Coating Bulk Density Increased by ⁇ 0.05-0.1 g/ml Tap Density (n 400) Slightly Increased by ⁇ 0.02-0.8 g/ml Flow Not Significantly/Slightly Better Flow Compressibility Index CI: Slightly Decreased by ⁇ 2-4% Mean Particle Size Significantly Increased Particle Shape/Surface Round and Even/Smooth and Flexible Physical Strength of Particle Relatively strong and Flexible
- FIG. 6 also shows that mean particle size of coated particles increased substantially as % coating was increased. These results indicate that the particulate coatings were well processed from the viewpoint of physical characteristics. The yield of Wurster process was always higher than 90%.
- gel-forming matrix requires several considerations. These include, e.g., how gel-forming material or matrix formers (e.g., a polymer and a gelation facilitator agent) can be effectively prepared, how the matrix formers can be uniformly blended with coated beads, and then how the final blend can be compressed into matrix tablets with no damage of coated beads.
- matrix formers e.g., a polymer and a gelation facilitator agent
- the bulk density and particle size of PEO/PEG powder blend are quite different from those of coated particles (see Tables 2 and 5). To achieve uniformity, the PEO/PEG powder mixture was physically modified to have similar physical characteristics to those of the Surelease® or Kollicoat® coated particles. In other words, the bulk density and particle size of the PEO/PEG powder mixture were increased to achieve uniform blending with the coated particles comprising Cevimeline.
- the physical modification could be made through dry or wet granulation of PEO/PEG either in the presence or in the absence of coated particles.
- the granulation will include a blending procedure.
- the PEO/PEG granules need to be soft (or flexible) enough not to damage the coated particles during compression.
- the granules must also serve as a filler of the matrix.
- FIG. 5 shows the overview for both the process development of PEO/PEG granulation and the compression of the final blend with coated drug.
- the physical characteristics for both coated beads and PEO/PEG granules were evaluated in terms of blending uniformity, compressibility and content uniformity of final tablets.
- the roller compaction process of the PEO/PEG powder blend was optimized.
- the roller compactor used is Fitzpatrick IR 220 Chilsonator.
- the roller compaction was directly followed by milling.
- the compacted ribbons were milled using a M5A Fitz Mill equipped with traditional blade rotor and 0.065 inches screen.
- the characterized properties of the RCDG product are shown in Table 7.
- the blending between the granules and the Surelease® coated beads was observed to be relatively uniform.
- the V-blender used is a P-K Blend Master.
- the formulation is presented in Table 8.
- GPCG-1 Versa Glatt with top-spray set was used for the fluid-bed granulation of PEO/PEG in the presence of coated drug.
- a formulation for a given tablet size (606 mg including 1% magnesium stearate) is presented as an example in Table 9.
- Table 10 lists changes to the physical characteristics after the FBG process. Prior to compression, the FBG product was blended again with the P-K V-blender for 5 minute to increase blending uniformity and mixed with magnesium stearate for additional 2 minutes.
- the final blends (those produced by fluid bed granulation by mixing PEO/PEG in the presence of coated particles) were compressed into tablets using PH-106-DMS Korsch rotary tablet press.
- Three different tablet toolings were individually mounted to the press, depending upon the tablet size and shape designed; 9.5 mm round/concave tooling for 404 mg tablet, 11.1 mm round/concave and 8.7 ⁇ 18.9 mm oval toolings for 606 mg tablet.
- Different compression forces yielding different hardness were tested to balance two requirements—physical stability of the tablets and minimal damage to the coated particles by the compressive force.
- the total tablet weight appears to influence the drug release profile.
- the amount of the coated particles was fixed and the amount of the gel-forming material was changed (% content of matrix formers).
- the PEO:PEG ratio was maintained at 4:3 for all tablets.
- the tablet that weighs 404 mg contained 199 mg of active agent-containing particles, 115 mg of PEO, 86 mg of PEG, and 6 mg of magnesium stearate; and the tablet that weighs '606 mg contained 199 mg active agent-containing particles, 229 mg of PEO, 172 mg of PEG, and 6 mg of magnesium stearate.
- the drug release rate was found to decrease over time for the Surelease® coated particles in matrix tablets. For instance, the tablets that weigh 404 mg showed 96% drug release for 12 hours in the case of Surelease® coated particle, while the tablets that weigh 606 mg showed only 83% release.
- FIG. 9 illustrates the drug release profile from conventional Cevimeline HCl matrix tablets. As shown in FIG. 9, Cevimeline was released in about 6 hours, and could not achieve 12-24 hour sustained release. This result illustrates that the gel matrix system alone is not sufficient to provide a sustained release of a hydrophilic active agent for up to 12-24 hours.
- FIG. 10 illustrates the drug release profiles from two different shaped 606 mg tablets comprising 100% Surelease® coated particles in PEO/PEG gel-forming matrix prepared by fluid-bed granulation (HPLC Method).
- One set of tablets were round/concave and were 11.1 mm in their dimension.
- the two different shaped tablets were made using the same batch of 100% Surelease® coating.
- the other set of tablets were oval and were 8.7 ⁇ 18.9 mm in dimension.
- both round and oval shaped tablets had 24 hours sustained drug release in water at 37° C. No significant difference in drug release profile was found between the round and oval tablets.
- the 100% Surelease® coated particle in the gel-forming matrix dosage form provides 18-24 hours extended release of Cevimeline HCl. Moreover, the results meet a desirable dissolution specification, wherein no more than 40% released at 1 hour, 75+15% released at 12 hours, and no less than 80% released at 24 hours.
- the tablets were compressed using Carver press with 3 ⁇ 8 inch concave punches and dies by direct compression.
- Cardizem SR pellets were manually placed on top of the first layer in the core region of the mixture.
- another layer of PEO/PEG mixture was then put on top of the pellets to maintain the active agent-containing pellets in the core region.
- the tablet was compressed with the pellets in the core.
- the present invention provides novel materials and methods for producing tablets. While specific examples have been provided, the above description is illustrative and not restrictive. Any one or more of the features of the previously described embodiments can be combined in any manner with one or more features of any other embodiments in the present invention. Furthermore, many variations of the invention will become apparent to those skilled in the art upon review of the specification. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.
Abstract
Description
- Not Applicable.
- Not Applicable.
- A variety of hydrogel-type preparations have been developed to effect the sustained release of orally ingested drugs. For example, Japanese patent application JP-A-62-120315 discloses a preparation obtained by compression-molding a drug, a hydrogel-forming water-soluble polymer and an enteric coating. JP-A-63-215620 discloses a hydrogel-type preparation with a core having a drug and a water-soluble polymer and an outer layer with a water-soluble polymer as a base. JP-B-40-2053 discloses a sustained-release preparation having a mixture of a drug and a high polymer of ethylene oxide and, as an optional component, a hydrophilic substance. However, all of these preparations are designed to release a drug continuously while the administered preparation is still retained in the upper digestive tract, typically in the stomach and small intestine. They were not intended to provide for a release of a drug in the lower digestive tract including the colon, where little water is available.
- Hydrophilic gel-forming preparations have been further developed so that they can provide a sustained release of orally ingested drugs throughout the digestive system, including in the lower digestive tract. For example, EP 0 661 045 describes a preparation adapted to absorb water into its core to undergo substantially complete gelation during its stay in the upper digestive tract. As the tablet moves down the digestive system in the form of a gel to the lower digestive tract, the preparation swells and the gelled outer surface of the tablet erodes gradually releasing the drug. This type of oral tablet is capable of providing a sustained release of the drug throughout the digestive tract, including in the colon.
- While the gel-forming preparations, such as those described in the EP 0 661 045, have many applications, they may not be suitable for certain types of active agents, particularly when the active agents are unstable in the gel-forming preparations or may be released in a manner that is not desirable. Thus, there exists a continuing need for improved forms of sustained release preparations which can continuously release an active agent throughout the digestive tract, regardless of the physical or chemical properties of the active agent. Moreover, many situations may require that an active agent be delivered to the patient in a non-random or pulsatile manner, or, that the active agent be delivered to a particular anatomic compartment, e.g., the colon. For example, if an easily degradable drug or a drug with a short biological half-life needs to be delivered to the colon, it cannot be released in the upper digestive tract. Thus, there is a need for tablets that are capable of providing delayed and/or pulsatile release of an active agent. The present invention fulfills these and other needs.
- The present invention provides, for the first time, a tablet and methods for making the tablet that comprises a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent from the tablet. These particles that comprise the active agent and the coating material are also referred to as “active agent-containing particle”, “coated particle” or “coated bead.” The gel-forming material forms a matrix (a “gel-forming matrix”) for the active agent-containing particles. The active agent-containing particle is formulated with a coating material so that it can modify or control the release of the active agent by, for example, slowing or inhibiting the passage of the active agent out of the tablet and into the digestive system. These tablets are also referred to as OCAS™ (oral controlled absorption system) matrix tablets herein.
- In some embodiments of the invention, the release of the active agent from the tablet can be modified and controlled by the combination of two systems: 1) the gel-forming matrix; and 2) the coating material in contact with the active agent. In the digestive system, the gel-forming matrix absorbs water to undergo substantially complete gelation during its stay in the upper digestive tract and moves down into the lower digestive tract undergoing constant erosion, continuously releasing the active agent-containing particles from the tablet. This erosion of the gel-forming matrix can control the release of the active agent-containing particles from the tablet. In addition to the gel-forming matrix, the coating material that is on or around the active agent provides another level of control in releasing the active agent from the tablet. For example, the coating material can modify or control the rate of diffusion of the active agent through the gel matrix and out of the tablet. Moreover, since the coating material provides a physical and/or chemical barrier for the active agent, any type of active agents can be included in the tablets of the present invention. The selection of the active agent is not restricted to those which are released from the tablet in a favorable manner.
- In one aspect, the invention is particularly useful for an active agent that is hydrophilic. In the case of water insoluble or less hydrophilic active agents, the erosion of the gel-forming matrix of the tablet precedes the diffusion of the active agent through the swollen gel layer of the tablet. Thus, the active agent release rate limiting step is typically the erosion of the gel-forming matrix. Therefore, with these active agents, the gel-forming matrix alone can provide enough control on-release of the active agent and can be used to design a sustained release of these active agents over, e.g., 12-24 hours. However, a hydrophilic active agent tends to diffuse out from the gel-forming matrix faster than the erosion of the swollen gel layer of the tablet. Thus, while a tablet comprising a gel-forming matrix may be useful for water insoluble or less hydrophilic active agents, the gel-forming matrix may not provide for sufficient controlled release for the hydrophilic active agent.
- FIG. 9 illustrates this diffusion problem for a hydrophilic active agent. As will be described in further detail below in Example 6B, a tablet comprising Cevimeline HCl (having a high water solubility of about 766 mg/ml at 25° C.) and a gel-forming matrix comprising a polyethylene oxide polymer (PEO) and a polyethylene glycol (PEG) was prepared. The active agent Cevimeline HCl as purchased (without further treatment) was mixed with the gel-forming material. FIG. 9 shows the drug release profile from this conventional Cevimeline HCl matrix tablet. As shown in FIG. 9, substantially all of the drug was released in about 6-8 hours from the tablet. The tablet did not provide for sustained release of the drug over, e.g., 12-24 hours.
- Thus, in the embodiments of the invention, a hydrophilic active agent, such as Cevimeline HCl, is physically and/or chemically modified to control its release rate from the tablet. Preferred embodiments of the invention provide a tablet comprising a gel-forming material and a particle comprising a hydrophilic active agent, wherein the particle is formulated to modify release of the active agent from the tablet. For example, the particle comprises a hydrophilic active agent in contact with a coating material (e.g., on or around the active agent). The coating material can slow or prevent the diffusion of the hydrophilic active agent out of the gel-forming matrix.
- An improvement in the release profiles of a hydrophilic drug from tablets according to embodiments of the invention are described in Example 6C and shown in FIG. 10. Example 6C describes an embodiment of the present tablet which comprises Cevimeline HCl in contact with a coating material in a gel matrx. As shown in FIG. 10, the release profiles of this modified Cevimeline HCl from the gel matrix tablet are much more gradual and linear than the release profile of unmodified Cevimeline HCl from the conventional matrix tablet shown in FIG. 9. Moreover, when FIGS. 9 and 10 are compared, it is clear that embodiments of the invention can provide a sustained release of a hydrophilic drug up to, e.g., 12-24 hours, compared to conventional gel matrix tablets without modification of the active agent.
- While the above example illustrates the use of the embodiments of the invention with a hydrophilic active agent, any suitable active agents, including a less hydrophilic active agent or a hydrophobic active agent, can be incorporated into embodiments of the invention. For example, embodiments of the invention are particularly useful for active agents that are unstable, or sensitive to moisture or oxidation. As an illustration, if the active agent is an enzyme, it may lose its activity if it is in contact with water or the gel-forming material for a prolonged period of time. By providing a physical and/or chemical barrier (e.g., a coating) on or around the active agent, the active agent is protected until it is released from the tablet to the body.
- As described above, these embodiments of the invention are capable of sustaining the efficacy of active agents for a prolonged period. One beneficial result is that the number of administrations can be reduced. For example, an individual needs to take a tablet comprising an active agent, such as a drug, only once a day or twice a day. In some cases, tablets can release a drug too quickly into the upper digestive tract of a person, resulting in undesirable side effects. Embodiment of the invention is capable of providing a constant concentration of the drug within the blood of a person. This may reduce potential side effects of the drug by suppressing rapid increases in blood concentration of the drug.
- In another aspect, the invention provides tablets and methods for making the tablets that can achieve programmable drug release profiles. For example, the tablets can be designed to have pulsatile, delayed onset or any suitable predetermined release profile. In one embodiment, this is achieved by designing a multilayered tablet. For example, different layers of the multilayered tablet can comprise different active agents, different amounts of active agent and/or different forms of active agent. In another example, different layers of the multilayered tablet can comprise different proportions of a polymer and a gelation facilitator agent, and/or different kinds of a polymer or a gelation facilitator agent. These embodiments provide additional control of the release of the active agents from the tablet. Thus, as the multilayered tablet slowly dissolves in its passage through the digestive tract, it releases varying amounts of active agent (or different active agents) at different times, i.e., in different anatomical compartments (e.g., small intestine versus colon). This effectively allows a programmable active agent release scheme. For example, it may be desirable to release larger amounts of active agent initially (to be absorbed, e.g., in the stomach or upper end of the small intestine) while gradually releasing diminishing amounts of active agent release as the tablet passes through to the end of the colon (or vice versa). Alternatively, it may be desirable that an active agent only be released in the colon. In another embodiment, one active agent (or form of the active agent) is released in the upper digestive tract (e.g., stomach or small intestine) and another active agent or a variation of the active agent is released in the lower digestive tract (e.g., large intestine or colon).
- Accordingly, in one aspect, the invention provides a tablet comprising: at least one particle comprising a hydrophilic active agent in contact with a coating material to modify release of the active agent, and a gel-forming material comprising: a polymer; and a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C.
- In one embodiment, the particle comprises an active agent and a coating material on or around the active agent.
- In another embodiment, the hydrophilic active agent has a water solubility of at least about 30 mg/ml at a temperature of about 25° C.
- In yet another embodiment, the hydrophilic active agent is a quinuclidine derivative or acetylcholine.
- In yet another embodiment, the active agent-containing particle has a size between about 50 μm to about 5 mm, preferably between about 100 μm to about 3 mm, and more preferably between about 300 μm to about 2 mm.
- In yet another embodiment, the tablet comprises a plurality of the active agent-containing particles and wherein the gel-forming material forms a matrix for the plurality of the particles.
- In yet another embodiment, the active agent is in the form of a crystal or a granule, and/or the particle comprises a plurality of active agent crystals or granules.
- In yet another embodiment, the coating material slows release of the active agent from the tablet.
- In yet another embodiment, the coating material is flexible.
- In yet another embodiment, the coating material is selected from the group consisting of a natural polymer, a semi-synthetic polymer, and a synthetic polymer. Examples of these polymers include chitosan, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, cellulose acetate membrane, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyacrylic acid, polyvinyl acetate, poly(vinylacetate phthalate), poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(lactic acid), poly(glycolic acid), poly(lactic/glycolic acid), poly(dimethyl silicone), poly(hydroxyethyl methacrylate), poly(ethylene/vinyl acetate), poly(ethylene/vinyl alcohol), or a mixture thereof.
- In yet another embodiment, the coating material further comprises a plasticizer, a stabilizer or both.
- In yet another embodiment, the polymer comprises a polyethylene oxide polymer.
- In yet another embodiment, the gelation facilitator agent comprises a polyethylene glycol.
- In yet another embodiment, the polymer to the gelation facilitator ratio is between about 1:9 to about 9:1 by weight, preferably between about 3:7 to about 7:3 by weight, more preferably between about 4:6 to about 6:4 by weight.
- In yet another embodiment, the tablet has a hardness of at least about 2 kp.
- In yet another embodiment, the tablet has a hardness between about 2 kp and about 10 kp.
- In yet another embodiment, the tablet provides a sustained release of the active agent for at least about 12 hours.
- In yet another embodiment, the tablet further comprises a non-hydrophilic active agent.
- In yet another embodiment, the tablet comprises at least two different types of particles with different active agents.
- In yet another embodiment, the particles in the tablet comprise at least two different types of particles with different coating materials.
- In yet another embodiment, the distribution of the particles in the tablet is non-random.
- In yet another embodiment, the tablet is a multilayered tablet.
- In yet another embodiment, at least two of the layers of the multilayered tablet comprise a different amount of the particles or at least two different types of active agents.
- In yet another embodiment, the particles in the tablet are concentrated at the core of the tablet.
- In yet another embodiment, the polymer comprises a polyethylene oxide polymer and the gelation facilitator agent comprises a polyethylene glycol.
- In another aspect, the invention provides a method for producing a modified tablet, the method comprising: (1) mixing a formulation comprising: (a) at least one particle comprising a hydrophilic active agent in contact with a coating material to modify release of the active agent; (b) a polymer; and (c) a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C.; and (2) compressing the formulation to produce the tablet. In these methods, any of the materials described herein can be used to produce a tablet. For example, in one embodiment of the methods, the particle comprises the active agent and a coating material on the active agent. In another example, the coating material is flexible so that it does not crack during compressing the formulation into the tablet. In yet another example, the coating material is hydrophobic.
- In one embodiment of the methods, the particle is produced by spraying the coating material on the active agent.
- In another embodiment, the polymer is granulated with the gelation facilitator agent in step (1).
- In yet another embodiment, the polymer and the gelation facilitator agent are granulated with the active agent-containing particles in step (1).
- These and other aspects of the present invention will become apparent to those skilled in the art from the following detailed description of the invention, the accompanying drawings, and the appended claims.
- FIG. 1A illustrates one embodiment of
tablet 101 comprising a gel-formingmatrix 10 andparticles 11, wherein the particles comprise an active agent and a coating material in contact with the active agent. - FIG. 1B illustrates an enlarged view of one embodiment of a particle11(a). The particle 11(a) comprises an active agent 12(a) and a coating material 13(a) on and around the active agent.
- FIG. 1C illustrates an enlarged view of another embodiment of a particle11(b). The particle 11(b) comprises a plurality of active agents 12(b) and a coating material 13(b) on and around the active agents. The particle 11(b) also comprises a plurality of active agents 12(c), wherein the coating material 13(b) is on, but not necessarily around the active agents.
- FIG. 2A illustrates another embodiment of
tablet 102 comprising a gel-formingmatrix 10 and a plurality of different types ofparticles - FIG. 2B illustrates an embodiment of
multilayered tablet 103 comprising two layers. Thecore region 10 comprisesparticles 11 and theouter region 15 is devoid of particles. - FIG. 2C illustrates another embodiment of
multilayered tablet 104 comprising three layers. Thecore region 10 comprises one type ofparticles 11, theintermediate region 14 comprises another type ofparticles 16, and theouter region 18 is devoid of particles. - FIG. 3 illustrates an overview of one embodiment of active agent pelletization/granulation development schemes.
- FIG. 4 illustrates one embodiment of coating process schemes to make coated particles or beads comprising active agent pellets or granules.
- FIG. 5 illustrates an overview of one embodiment of granulation and tabletting processes.
- FIG. 6 illustrates a relationship between the amount of coating in particles versus the mean particle size for one embodiment of the invention.
- FIG. 7 illustrates the effect of coating amount applied on drug release from the coated particles.
- FIG. 8 illustrates drug release profiles from 606 mg tablets comprising 100% Kollicoat® coated particle in the PEO/PEG matrix prepared by fluid-bed granulation (HPLC method, n=3).
- FIG. 9 illustrates drug release profile from conventional Cevimeline HCl-PEO/PEG matrix tablet (HPLC method, n=6).
- FIG. 10 illustrates release profiles from two different shaped 606 mg tablets composed of 100% Surelease® coated particles in PEO/PEG matrix prepared by fluid-bed granulation (HPLC method).
- FIG. 11 illustrates dissolution profiles of tablets comprising SR pellets in the core of the tablet.
- “A sustained release tablet” refers to a tablet which is capable of releasing an active agent to the body for a prolonged period of time, e.g., for at least about 8 hours, preferably for at least about 12 hours, more preferably for at least about 16 hours, and most preferably for up to about 18-24 hours. Preferably, a sustained release tablet releases the active agent from the tablet gradually into the body. For example, a sustained release tablet that is designed to release of the active agent for about 18-24 hours preferably has the following dissolution specification using the dissolution test method described in Example 6A: no more than 40% of the active agent (e.g., by weight) released in 1 hour, about 70-85% of the active agent released in 12 hours, and no less than about 80% of the active agent released at 24 hours. In another example, a sustained release tablet is designed to release the active agent at a nearly linear zero order rate (typically when the active agent dissolution is measured up to 70% of the active agent release).
- The “size” of active granules or pellets, or coated beads or coated particles refers to the average dimension and can be measured by either laser diffraction sizer analysis or mechanical siever such as Ro-Tap.
- Unless specified otherwise, a range of “molecular weight” of a polymer (e.g., a polyethylene oxide polymer) or a gelation facilitator agent (e.g., a polyethylene glycol) described below is a weighted average molecular weight (measured by gel permeation chromatography).
- The term “cps” or “centipoise” is a unit of viscosity=m Pascal second. The viscosity is measured by Broolfield or other viscometers. See, e.g., Wang (1998)Clin. Hemorheol. Microcirc. 19:25-31; Wang (1994) J. Biochem. Biophys. Methods 28:251-61; Cooke (1988) J. Clin. Pathol. 41:1213-1216.
- Tablet “hardness” is physical strength measurement of the tablet. The resistance of a tablet to chipping, abrasion, or breakage under conditions of storage, transportation and handling before usage depends on its hardness, or “crushing strength.”The tablet “crushing” or “tensile” strength is defined as the force required to break a tablet by compression in the radial direction. It is typically measured using one of the many commonly available tablet hardness testers. For example, “Stokes” and “Monsanto” hardness testers measure the force required to break the tablet when the force generated by a coil spring is applied diametrically to the tablet. A “Strong-Cobb” hardness tester also measures the diametrically applied force required to break a tablet, the force applied by an air pump forcing a plunger against the tablet placed on an anvil. Electrically operated hardness testers, such as the Schleuniger apparatus (also known as a “Heberlein”) can be used. See also, TS-50N, Okada Seiko Co., Japan; Bi (1996)Chem. Pharm. Bull. (Tokyo) 44:2121-2127. The tablet hardness can be represented by various units, including in the units of kilopounds (“kp”).
- The “gelation index” or “percent gelation” as used herein represents the percentage of the portion of the tablet which has undergone gelation. The method of calculating the gelation index is not particularly limited but the following calculation method may be mentioned as an example. Using The Pharmacopeia of Japan XII (referred to “JP” hereinafter)
Disintegration Test Fluid 2, a gelation test can be carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. The test tablet is moistened for a predetermined time. The test tablets are then taken out at predetermined intervals, the gel layer is removed and the diameter (D obs) of the portion not forming a gel can be measured. From this D obs value, the gelation index (G) can be calculated (see the equation below). - D obs: The diameter of the portion not gelled after initiation of test
- D ini: The diameter of the preparation before initiation of test
- As an alternative to measuring the diameter of the tablet, other parameters, such as volume, weight or thickness, of the tablet can be measured to calculate a gelation index.
- In one aspect, the invention provides a modified tablet comprising a gel-forming material and at least one particle comprising an active agent, wherein the particle is formulated to modify release of the active agent from the tablet (e.g., the active agent in contact with a coating material). The gel-forming material forms a matrix (i.e., a gel-forming matrix) for the active agent-containing particles in the modified tablet. In some preferred embodiments, the particle comprises an active agent and a coating material on or around the active agent, wherein the coating material modifies the release of the active agent from the tablet. The combination of the gel-forming matrix and the particle comprising a coating material can provide any desired active agent release profile. For example, embodiments of the invention can provide a sustained release of a hydrophilic drug from the tablet for at least 8 hours, preferably up to between about 12-24 hours. Depending on the ultimate use of the tablets, these tablets typically comprise components that are physiologically or pharmacologically acceptable.
- The gel-forming material may comprise: (1) a polymer; and (2) a gelation facilitator agent having a solubility higher than about 0.1 gram/ml in water at a temperature of about 20° C. The polymer is water insoluble and contributes to forming a network of materials within the matrix which can swell upon absorbing water. The gelation facilitator agent is a hydrophilic base that draws water into the core of the gel-forming matrix of the tablet, thereby allowing a substantially complete gelation of the entire tablet before the tablet reaches the large intestine. Different forms and/or types of the polymers and the gelation facilitator agent can be used to modify the gelation rate and/or erosion rate of the gel matrix. They can be selected to provide a controlled release pattern of the active agent-containing particles. Other additives can be incorporated to further modify the gelation and/or release pattern of the active agent.
- The particle is formulated to further modify the release of the active agent (in particular the hydrophilic agent) from the tablet. Typically, the particle comprises an active agent and a coating material on, and preferably around, the active agent. The active agent can be in any suitable form. In certain embodiments, the active agent can be in the form of a crystal, a granule, or a pellet. These active agent forms may facilitate certain coating processes of the active agents. Moreover, the particle can comprise a single active agent crystal (or granule or pellets) or can comprise a plurality of active agent crystals (or granules or pellets).
- In another aspect, the tablets are designed to have pulsatile or delayed onset release profiles. This can be achieved by designing, e.g., a multilayered tablet. Different layers of the multilayered tablet can have different active agents, different amounts of active agents, different forms of active agents, different amounts or kinds of coating materials, different amounts or kinds of gel-forming materials, etc.
- Embodiments of the invention are illustrated by referring to the figures. As shown in the figures, active agent-containing particles can be distributed randomly (see, e.g., FIG. 1A) or can be distributed non-randomly (see, e.g., FIGS.2A-2C).
- FIG. 1A illustrates one of many examples of the modified tablet according to an embodiment of the invention.
Tablet 101 comprises a plurality of active agent-containingparticles 11 and a gel-formingmaterial 10 surrounding the particles. Additional details regarding the active agents and gel-forming materials are described below. - FIG. 1B illustrates an enlarged view of an active agent-containing particle11(a). Particle 11(a) comprises an active agent 12(a) as a core element and a coating material 13(a) on and around the active agent 12(a).
- FIG. 1C illustrates an enlarged view of another example of another active agent-containing particle11(1 b). Particle 11(1 b) comprises a plurality of active agents 12(b) and a coating material 13(b) on and around the plurality of active agents 12(b). Particle 11(b) also comprises a plurality of active agents 12(c) and a coating material 13(b) on, but not necessary around all of the active agents 12(c). As shown in FIG. 1C, the plurality of active agents 12(b) and 12(c) can be dispersed throughout the coating material 13(b).
- FIG. 2A illustrates another example of a tablet according to an embodiment of the invention.
Tablet 102 comprises a plurality of different types ofparticles matrix 10. Each particle may have the same or different form. For instance, theparticles Particles particles particles 11 near the outer surface of thetablet 102 can be suitable for release into the upper digestive tract, while theparticles 16 and 17 in the inner region of thetablet 102 can be suitable for release into the lower digestive tract. Still alternatively,particles particles - FIG. 2B illustrates another example of the tablets according to an embodiment of the invention.
Tablet 103 is a multilayered tablet, wherein thecore portion 10 comprisesparticles 11 and theouter portion 15 is devoid of particles. Each portion can comprise different types of gel-forming material to further control the release of the particles comprising an active agent. This type of tablet is particularly useful to delay the onset of release of the active agent from thetablet 103. For example, it may be desirable that a drug only be released in the colon. In this example, theouter portion 15 can erode as the tablet passes through the upper digestive tract. When the tablet reaches the colon, the outer portion has eroded away and erosion of the gel-forming material of the core portion can begin, resulting in the release of the active agent-containing particles into the colon. - FIG. 2C illustrates yet another example of a tablet according to an embodiment of the invention. The
tablet 104 comprises three layers. Thecore portion 10 comprises active agent-containingparticles 11, theintermediate portion 14 comprises active agent-containingparticles 16, and theouter portion 18 is devoid of particles.Particles particles particles portion - Embodiments of the invention shown in FIGS. 1 and 2 are merely illustrative, and other variations are readily determinable by those skilled in the art. For example, embodiments of the tablet can further include untreated active agents (e.g., without coating material or in powders) in addition to active agent-containing particles.
- I. Active Agents and Pelletization/Granulation Development
- Any suitable active agent can be incorporated into the embodiments of the invention. Preferably, the active agent is a drug. However, the active agent is not necessarily limited to a drug, but can be a nutritional additive (e.g., vitamin), a placebo, or a reagent (e.g., a diagnostic reagent, a radioimaging reagent, or a magnetic imaging reagent).
- In one embodiment, the active agent is hydrophilic and has a water solubility of at least about 30 mg/ml at a temperature of about 25° C. Optionally, a hydrophilic active agent has a water solubility of at least about 50 mg/ml, at least about 100 mg/ml, at least about 200 mg/ml, at least about 300 mg/ml, at least about 400 mg/ml, at least about 500 mg/ml, at least about 600 mg/ml, at least about 700 mg/ml, at least about 800 mg/ml, at least about 900 mg/ml, at least about 1,000 mg/ml, at least about 1,200 mg/ml, or at least about 1,500 mg/ml at a temperature of about 25° C. Examples of a hydrophilic active agent include, cevimeline HCl, pseudoephedrin HCl, pyrilamine maleate, phenmetrazine HCl, hyoscyamine sulfate, edophonium HCl, doxylamine succinate, hydroxyzine HCl, fluphenazune HCl, niacinamide, etc.
- In certain embodiments, the active ingredient of the tablet is (+/−)-cis-2-methylspiro [1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate; also known as SNI-2011, cevimeline hydrochloride, AF102B, SND-5008, and FKS-508. SNI-2011 is a rigid analogue of acetylcholine. See, e.g., Iga (1998)Jpn. J. Pharmacol. 78:373-380; Iwabuchi (1994) Arch. Int. Pharmacodyn. Ther. 328(3):315-25. It is distributed by, e.g., Snow Brand Milk Product Co., Shinjuku-Ku, Tokyo, Japan. Quinuclidine salt derivative analogues of SNI-2011 can also be used. SNI-2011 and analogues are highly water soluble drugs, having a water solubility of about 1,400 mg/ml at 25° C. Cevimeline hydrochloride has a water solubility of 766 mg/ml at 25° C. They specifically bind to specific muscarinic receptors in various exocrine glands. They have demonstrated beneficial effects on xerostomia and keratoconjunctivitis sicca in patients with Sjogren's syndrome, see, e.g., Iwabuchi (1994) Gen. Pharmacol. 25:123-129.
- Preferably, the daily dose of these and other drugs that can achieve 18-24 hour extended release is incorporated into the tablet. Typically, about 1 mg to about 500 mg, optionally about 10 mg to about 200 mg, optionally 50 mg to about 100 mg, or optionally about 75 mg to about 90 mg of the active agent, e.g., Cevimeline hydrochloride, is incorporated into the tablet. This dosage could accommodate once a day dosing of the active agent. Typically, the weight percent of the active agent itself can be between about 0.5% to about 50% of the total tablet weight.
- In another embodiment, an active agent can be non-hydrophilic (e.g., hydrophobic) or can have a water solubility of less than, e.g., 30 mg/ml or 20 mg/ml at a temperature of about 25° C.
- In yet another embodiment, an active agent is a drug that is unstable if it is in contact with water or a gel-forming matrix for a prolonged period of time (e.g., sensitive to moisture or oxidation). These active agents may benefit by having a physical and/or chemical barrier (e.g., a coating material) on or around the active agents. Examples of unstable drugs include antibiotic drugs such as efrotomycin, milbemycins, tylosin derivatives, avermectins, ivermectin, mocimycin, goldinomycin, and the like.
- Any other suitable active agents can be included in the embodiments of the invention. For example, the active agents include, but are not limited to, e.g., anti-inflammatory, antipyretic, anticonvulsant and/or analgesic agents such as indomethacin, diclofenac, diclofenac Na, codeine, ibuprofen, phenylbutazone, oxyphenbutazone, mepirizol, aspirin, ethenzamide, acetaminophen, aminopyrine, phenacetin, scopolamine butylbromide, morphine, etomidoline, pentazocine, fenoprofen calcium, etc; tuberculostats such as isoniazid, ethambutol hydrochloride, etc.; cardiocirculatory system drugs such as isosorbide dinitrate, nitroglycerin, nifedipine, barnidipine hydrochloride, nicardipine hydrochloride, dipyridamole, arinone, indenolol hydrochloride, hydralazine hydrochloride, methyldopa, furosemide, spironolactone, guanethidine nitrate, reserpine, amosulalol hydrochloride, amitriptyline hydrochloride, neomapride, haloperidol, moperone hydrochloride, perphenazine, diazepam, lorazepam, chlordiazepoxide, diltiazem, ™etc.; antihistaminic agents such as chlorpheniramine maleate, diphenhydramine hydrochloride, etc.; vitamins such as thiamine nitrate, tocopherol acetate, cycothiamine, pyridoxal phosphate, cobamamide, ascorbic acid, nicotinamide, etc.; antigout agents such as allopurinol, colchicine, probenecid, etc.; hypnotic sedatives such as amobarbital, bromovalerylurea, midazolam, chloral hydrate, etc.; antineoplastic agents such as fluorouracil, carmofur, aclarubicin hydrochloride, cyclophosphamide, thiotepa, etc.; anticongestants such as phenylpropanolamine, ephedrine, etc.; antidiabetics such as acetohexamide, insulin, tolbutamide, etc.; diuretics such as hydrochlorothiazide, polythiazide, triamterene, etc.; bronchodilators such as aminophylline, formoterol fumarate, theophylline, etc; antitussives such as codeine phosphate, noscapine, dimemorfan phosphate, dextromethorphan, etc; antiarrhythmic agents such as quinidine nitrate, digitoxin, propafenone hydrochloride, procainamide, etc.; surface anesthetics such as ethyl aminobenzoate, lidocaine, dibucaine hydrochloride, etc.; antiepileptics such as phenytoin, ethosuximide, primidone, etc.; synthetic adrenocortical steroids such as hydrocortisone, prednisolone, triamcinolone, betamethasone, etc.; digestive system drugs such as famotidine, ranitidine hydrochloride, cimetidine, sucralfate, sulpiride, teprenone, plaunotol, etc.; central nervous system drugs such as indeloxazine, idebenone, tiapride hydrochloride, bifemelane hydrochloride, calcium hopantenante, etc.; hyperlipemia treating agents such as pravastatin sodium etc.; and antibiotics such as ampicillin phthalidyl hydrochloride, cefotetan, josamycin and so on. Typical drugs among the above drugs is nicardipine hydrochloride, SNI-2011, nifedipine, ditilazem hydrochloride, phenylpropanolamine hydrochloride, indomethacin, potassium hydrochloride, diazepamtheophylline, verapamil, morphine, and the like.
- In the embodiments of the invention, the active agent can be in any suitable form. For example, it can be in the form of a particle, powder, a crystal, a granule (i.e., an aggregate of smaller units of active agent, also referred to as a pellet). Depending on the methods used to coat the active agents to produce a particle, the active agents may be used as purchased (in the form of a powder or a crystal) or may be processed to form active agent granules or pellets. For example, if active agent granules or pellets are spray coated with a coating material to form coated active agent-containing particles, the active agents are preferably granulated or pelletized to improve the chemical or physical characteristics of the active agents for coating processes. For certain coating processes, it may be preferable that active agents are in the form of a granule or a pellet that has relatively high density and hardness, and relatively low brittleness and surface area.
- An active agent can be pelletized or granulated using any suitable methods known in the art. Pelletization or granulation is commonly defined as a size-enlargement process in which small particles are gathered into larger, permanent aggregates in which the original particles can still be identified. FIG. 3 illustrates one of many examples of an overview of pelletization or granulation development with one embodiment of the active agent (i.e., Cevimeline HCl). Prior to granulation, a binder can be added to the active agent to improve the granulation process. Examples of a suitable binder include, hydroxypropyl cellulose (HPC), a mixture of polyethylene oxide and polyethylene glycol, acacia, carbomer, carboxymethylcellulose sodium, ethylcellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl methylcellulose, maltodextrin, povidone, pregelatinized starch, zein, starch, and the like. Other additives can be added during granulation. These include, e.g., sweeteners, flavors, color agents, antioxidants, etc.
- Optionally, water or other solvent can be added to aid the granulation process. The amount of water or solvent added depends on, e.g., the selection of a granulation process, and is readily determinable by those of skill in the art. Water or other solvent may be added at any suitable time point during the granulation process. For example, a binder may be mixed with a solvent (e.g., water) to form a binder solution, and then the binder solution can be sprayed onto active agents. Alternatively, if a binder solution is too viscous to be uniformly sprayed onto active agents, it may be desirable to blend the binder with the active agent first and then spray water or other solvent to produce uniform pattern of active agent granules or pellets.
- Any suitable granulation methods can be used to produce particles comprising an active agent. By definition, granulation is any process of size enlargement whereby small particles are gathered together into larger, permanent aggregates to render them into a free-flowing state. For example, either wet granulation or dry granulation methods can be used.
- Dry granulation refers to the granulation of a formulation without the use of heat and solvent. Dry granulation technology generally includes slugging or roll compaction. Slugging consists of dry-blending a formulation and compressing the formulation into a large tablet or slugs on a compressing machine. The resulting tablets or slugs are milled to yield the granules. Roller compaction is similar to slugging, but in roller compaction, a roller compactor is used instead of the tableting machines. See, e.g.,Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, eds., Marcel-Dekker, Inc. pages 102-103 (1997). Dry granulation technique is useful in certain instances, e.g., when the active agent is sensitive to heat or solvent.
- Alternatively, wet granulation can be used. In wet granulation, solvents and binders are typically added to a formulation to provide larger aggregates of granules. The temperature during granulation can be set at any suitable point, generally not exceeding the melting point of any components of the formulation. Typically, the mixture is granulated at a temperature of about 35° C. to about 65° C. for about 20 to 90 minutes. Then the granules are typically air dried for a suitable duration (e.g., one or more hours).
- Preferably, the active agents are granulated with high shear mixer granulation (“HSG”) or fluid-bed granulation (“FBG”). Both of these granulation processes provide enlarged granules or pellets but differ in the apparatuses used and the mechanism of the process operation. In HSG, blending and wet massing is accomplished by high mechanical agitation by an impeller and a chopper. Mixing, densification, and agglomeration of wetted materials are achieved through shearing and compaction forces exerted by the impeller. The primary function of the chopper is to cut lumps into smaller fragments and aid the distribution of the liquid binder. The liquid binder is either poured into the bowl or sprayed onto the powder to achieve a more homogeneous liquid distribution.
- On the other hand, fluidization is the operation by which fine solids are transformed into a fluid-like state through contact with a gas. At certain gas velocities, the fluid will support the particles, giving them freedom of mobility without entrainment. Such a fluidized bed resembles a vigorously boiling fluid, with solid particles undergoing extremely turbulent motion, which increases with gas velocity. Fluidized bed granulation is then a process by which granules are produced in fluidized bed by spraying a binder solution onto a fluidized powder bed to form larger granules. The binder solution can be sprayed from, e.g., a spray gun positioned at any suitable manner (e.g., top or bottom). The spray position and the rate of spray may depend on the nature of the active agent and the binder used, and are readily determinable by those skilled in the art.
- These granulation techniques can be performed using commercially available apparatuses. For example, the HSG can be performed using Aeromatic-Field GP1/SP General Processor. Depending on the properties of the active agent, the HSG process is preferred. For example, when Cevimeline HCl was granulated using either HSG or FBG processes, it was found that the HSG process generated the Cevimeline HCl granules or particles of higher density than the FBG process.
- Optionally, granulated active agents can be milled. Milling can be performed using any commercially available apparatuses (e.g., Comil equipped with a 0.039 inch screen). The mesh size for the screen can be selected depending on the size of the active agent granule or pellet desired. Typically, the mesh size can range from 0.331 inch screen (mesh 20) to 0.006 inch screen (mesh 100). The milling process aids in providing relatively uniform active agent granules. After the granulated active agents are milled, they may be further dried (e.g., in the air) if desired.
- Typically, the mean size of the active agent granule or pellet can range from about 50 μm to about 3 mm, optionally about 100 μm to about 2 mm, or optionally about 300 μm to about 1 mm. Typically, the bulk density or the tap density of the active agent granules or pellets range from about 0.1 g/ml to about 1.5 g/ml, optionally about 0.3 g/ml to about 0.8 g/ml, optionally about 0.4 g/ml to about 0.6 g/ml. Bulk density is measured based on USP method (seeUS Pharmacopoeia, edition XXIV, pages 1913-1914, testing method <616>, incorporated herein by reference).
- II. Preparation of Particles Comprising an Active Agent and a Coating Material
- Active agents (as purchased or as pelletized) are processed to form a particle with a coating material, wherein the coating material is in contact with the active agents to modify the release of the active agents. For example, the particle comprises an active agent and a coating material on or around the active agent as shown in FIG. 1B or1C. Advantageously, this physical/chemical modification of the active agent provides improved sustained or controlled release of active agents from the tablet. Besides controlling active agent release pattern, physical modification of the active agent using encapsulation, granulation, and/or polymer coating techniques has many advantages such as less inter- intra-individual variation, a very reduced influence of gastric emptying and intestinal transit time, reduced influence of pH, viscosity and consequently of food and of the position of the body as well as gastroresistance and taste-masking.
- Any suitable coating material may be used with the embodiments of the invention. For example, the coating material can be a natural polymer, a semi-synthetic polymer, or a synthetic polymer. These include, but are not limited to, chitosan, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, cellulose acetate membrane, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyacrylic acid, polyvinyl acetate, poly(vinylacetate phthalate), poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(lactic acid), poly(glycolic acid), poly(lactic/glycolic acid), poly(dimethyl silicone), poly(hydroxyethyl methacrylate), poly(ethylene/vinyl acetate), poly(ethylene/vinyl alcohol), polyamides, polyesters, polyurethanes, polyureas, or a mixture thereof.
- In one embodiment, the coating material is less hydrophilic than the active agent so that the coating material inhibits the diffusion of the hydrophilic active agent through the tablet. Typically, a water insoluble or hydrophobic coating material can be used. Examples of a hydrophobic coating material include ethyl cellulose, polymethacrylic polymers, polyvinylacetate, cellulose acetate polymers, etc. In another embodiment, the coating material is flexible so that it is flexible to withstand the compression pressure during the production of compressed tablets. A tablet is generally compressed to a hardness of at least about 2 kp, typically between about 2 kp to about 10 kp. Accordingly, the coating material preferably comprises sufficient flexibility, plasticity, or elasticity so that it does not deform (e.g., crack or break) during the tablet compression of at least about 2 kp. A plasticizer may be included in the coating material to increase the flexibility of the coating material. Examples of a plasticizer include benzyl benzoate, chlorobutanol, dibutyl sebacate, diethyl phthalate, clycerin, mineral oil, polyethylene glycol, sorbitol, triacetin, triethyl citrate, etc. Optionally, a stabilizer, such as acacia, bentonite, cyclodextrins, glyceryl monostearate, propylene glycol, white or yellow wax, Xanthan gum, etc., can be added to a coating material.
- Some of these coating materials are in the form of an aqueous polymeric dispersion and are commercially available. For example, these include Surelease® (ethyl cellulose), Eudragit™ RS/NE (polyacrylic polmers) and Kollicoat® SR (polyvinylacetate), etc. Typically, these commercially available coating materials include a plasticizer and/or a stabilizer.
- Depending on the selection of a coating method, a single active agent crystal or granule or a plurality of active agent crystals or granules can be coated to form a single particle. For example, with reference to FIG. 1B, the particle11(a) may comprise a single active agent crystal or granule 12(a) and coating material 13(a) on and around the active agent. These particles can be produced by, e.g., spraying a coating material on an individual active agent crystal or granule. In another example with reference to FIG. 1C, the particle 11(b) may comprise a plurality of active agents (powders, crystals, or granules) 12(b) and 12(c) and coating material 13(b) on or around the active agents. Particles as shown in FIG. 1C can be produced by, e.g., applying the coating material on the active agent powder, crystals or pellets and then chopping (and optionally milling) the coated mixture into particles. The particles comprising the active agent and the coating materials are herein also referred to as beads or coated beads or coated particles.
- Any suitable coating methods can be used to produce particles comprising an active agent and a coating material on or around the active agent. For example, either a type A or a type B coating or encapsulation process can be used.
- Type A processes include simple or complex coacervation, interfacial polymerization in liquid media, in-liquid drying, thermal and ionic gelation in liquid media, or desolvation in liquid media techniques. In one embodiment of type A processes, a coacervation process can be used. In both simple and complex coacervation processes, the water phase is utilized as the continuous phase (see, e.g., Ertan (1997)J. Microencapsul. 14:379-388; Tuncel (1996) Pharmazie 51:168-171). In addition, water soluble polymers can be used in the coacervation process. Typical coating or microencapsulating polymers include, e.g., polyamides, polyesters, polyurethanes, and the polyureas and the like.
- In another embodiment, the interfacial polymerization process can be used. In this process, two polymeric monomer suspensions are used—a discontinuous phase comprising particles comprising active agents to be encapsulated and a continuous phase for coating films. The two monomers react at the interface between the core and the continuous phase, causing polymerization under controlled process conditions.
- In yet another embodiment, a phase separation technique can be used (see, e.g., Mandal (1998)Drug Dev. Ind. Pharm. 24:623-629). In this technique, a polymer of discontinuous phase is generally phased out or desolvated from the solvent continuous phase. This polymer of discontinuous phase will deposit around a reservoir such as a liquid droplet or a solid particle as a polymer wall. The polymer can be deposited either by temperature differential, by the introduction of a second polymer, or by the evaporation of the solvent.
- Type B processes utilize spray drying, spray chilling, fluidized bed coating, spray drying, pan coating, and spray coating, electrostatic deposition, centrifugal extrusion, spinning disk or rotational suspension separation, polymerization at liquid-gas or solid-gas interface, pressure extrusion or spraying into solvent extraction bath techniques. Pan coating can be utilized for multiple layer coatings of the tablet (see, e.g., Heinamaki (1997)Pharm. Dev. Technol. 2:357-364). Fluid bed coating, referred to as Wurster coating, and spray drying techniques can also be utilized for coating the active agent (see, e.g., Jono (1999) Chem. Pharm. Bull. (Tokyo) 47:54-63; Miyamoto (1997) Chem. Pharm. Bull. (Tokyo) 45:2043-2050).
- The selection of a suitable coating process depends on the physical and chemical characteristics of the active agent, the coating material, etc. and is determinable by those skilled in the art. For instance, when a spray system is used to coat the active agents, it may be desirable to use a coating material that does not have a high tack in its formula which could lead to clogging of the nozzle of the spray system.
- Any suitable amount of coating material can be applied on the active agent as long as the coating provides sufficient diffusion or protective barrier for the active agent. Typically, about 20% to about 150% of the coating is applied to the active agent granule, wherein the % coating means % ratio (w/w) of the amount of coating polymer used to the amount of active agent granule (and a binder and other materials in the granule). Preferably, about 30% to about 80% of coating is applied. More preferably, about 40% to about 60% of coating is applied.
- Depending on the amount of coating material-applied, the mean size of the particles can range, e.g., from about 50 μm to about 5 mm, optionally about 100 μm to about 3 mm, or optionally about 300 μm to about 2 mm. Typically, the bulk density or the tap density of these particles are slightly higher than uncoated active agent granules or pellets. For example, the bulk density or the tap density of the particles can range from about 0.1 g/ml to about 5 g/ml, optionally about 0.3 to about 3 g/ml, optionally about 0.5 g/ml to about 1.0 g/ml. Preferably, the particles are round, even, and smooth. Also preferably, the particles are relatively strong and yet flexible.
- Any suitable amount of active agent-containing particles can be included into the final formulation. Typically, about 5% to about 60% of active agent-containing particles by weight to the total weight of the tablet are included. The selection of a suitable amount of active agent-containing particles depends on the dosage desired and is readily determinable by those skilled in the art.
- III. Gel-Forming Material and Combining Gel-Forming Material and Active Agent-Containing Particles to Produce Tablets
- The active agent-containing particles are then blended with a gel-forming material, and the final blend is compressed into tablets without damaging the particles. The gel-forming material forms a matrix for the particles and comprises a polymer and a gelation facilitator agent. The polymer provides a structural basis for the matrix of the tablet to swell upon absorbing water. The gelation facilitator agent is a hydrophilic base that draws water into the core of the gel-forming matrix, thereby allowing substantially gelation of the entire tablet. By incorporating the gelation facilitator agent, the gel-forming matrix absorbs water to undergo substantially complete gelation during its stay in the upper digestive tract and moves into the lower digestive tract undergoing constant erosion, continuously releasing the active agent-containing particles.
- The polymer in the gel-forming matrix has physical characteristics, inclusive of viscosity in the gelled state, which permits the tablet to retain its shape more or less during its travel down to the lower digestive tract, including the colon, withstanding the contractile forces of the digestive tract associated with the digestion of food. The properties of the polymer depends on its molecular weight, viscosity, etc. The polymer used in the present invention typically has an average molecular weight ranging from about 0.5×106 daltons to 10×106 daltons, more typically ranging from 1×106 daltons to 8×106 daltons. Preferably, the polymer component in the gel-forming material has an average molecular weight of at least about 1×106 daltons and has a viscosity of at least about 1,000 cps in a 1% water solution at a temperature of about 25° C. (i.e., if 1% by weight of PEO is added to water, the aqueous solution containing PEO has a viscosity of at least about 1,000 cps). More preferably, the polymer has an average molecular weight of at least about 2×106 daltons, even more preferably between about 5×106 daltons to about 10×106 daltons. If desired, any mixture of two or more polymers can be used included in the gel-forming material.
- Among such polymers are polyethylene oxide (PEO) [e.g., Polyox WRS-303 (average mol. wt.: 7×106; viscosity: 7500-10000 cps, 1% in H2O, 25° C.), Polyox WSR Coagulant (average mol. wt.: 5×106; viscosity: 5500-7500 cps, under the same condition above), Polyox WSR-301 (average mol. wt.: 4×106 viscosity: 1650-5500 cps, under the same condition above), Polyox WSR-N-60K (average mol. wt.: 2×106; viscosity: 2000-4000 cps, 2% in H2O, 25° C.), all of which are trade names of Union Carbide Co.]; hydroxypropylmethylcellulose (HPMC) [e.g., Metolose 90SH10000 (viscosity: 4100-5600 cps., 1% in H2O, 20° C.), Metolose 90SH50000 (viscosity: 2900-3900 cps, under the same condition above), Metolose 90SH30000 (viscosity: 25000-35000 cps, 2% in H2O, 20° C.), all of which are trade names of Shin-Etsu Chemicals Co.]; sodium carboxymethylcellulose (CMC-Na) [e.g., Sanlose F-150MC (average mol. wt.: 2×105, viscosity: 1200-1800 cps, 1% in H2O, 25° C.), Sanlose F-1000MC (average mol. wt.: 42×104; viscosity: 8000-12000 cps, under the same condition above), Sanlose F-300MC (average mol. wt.: 3×105; viscosity: 2500-3000 cps, under the same condition above), all of which are trade names of Nippon Seishi Co., Ltd.]; hydroxyethylcellulose (HEC) [e.g., HEC Daicel SE850 (average mol. wt.: 148×104; viscosity: 2400-3000 cps, 1% in H2O, 25° C.), HEC Daicel SE900 (average mol. wt.: 156×104; viscosity: 4000-5000 cps, under the same condition above), all of which are trade names of Daicel Chemical Industries]; carbonxyvinyl polymers [e.g., Carbopol 940 (average mol. wt.: ca. 25×105; B. F. Goodrich Chemical Co.) and so on.
- In a preferred embodiment, a PEO is used as a polymer as part of the gel-forming material. Where a continuous release of the drug over a long time, for example more than 12 hours, is desired, a polymer having a higher molecular weight, preferably an average molecular weight of more than 4×106 daltons, or a higher viscosity, preferably a viscosity of more than 3000 cps at a concentration of 1% in water at 25° C., is preferable.
- Another component of the gel-forming material is a gelation facilitator agent. The gelation facilitator agent can be at least one excipient having solubility higher than 0.1 g/ml in water at room temperature (e.g., 20° C.). The gelation facilitator agent allows water to penetrate into the core of the tablet. The higher the solubility of the gelation facilitator agent in water, the more effective it is in allowing into the core of the tablet. Preferably, the gelation facilitator agent has water solubility of at least about 0.2 g/ml, more preferably at least about 0.25 g/ml, most preferably at least about 0.3 g/ml at room temperature (e.g., 20° C.).
- Examples of such gelation facilitator agent include highly hydrophilic polymers such as different molecular weight polyethylene glycol (PEG), e.g., polyethylene glycols (PEG), e.g. PEG400, PEG800, PEG100, PEG1200, PEG1500, PEG2000, PEG4000, PEG6000, PEG8000, PEG10000 and PEG20000, and the like (produced by, e.g., Nippon Oils and Fats Co.), or mixtures thereof. Other highly hydrophilic polymers that can be used as gelation facilitator agents include polyvinylpyrrolidone (PVP; e.g. PVP K30™, PVP K90™ from BASF), hydroxyethylcellulose, hydroxypropylcellulose and the like; sugar alcohols such as D-sorbitol, xylitol, etc.; sugars such as sucrose, anhydrous maltose, D-fructose, dextran (e.g. dextran 40), glucose, etc.; surfactants such as polyoxyethylene-hydrogenated castor oil (HCO; e.g. Cremophor RH40™ produced by BASF, HCO-40™ and HCO-60™ produced by Nikko Chemicals Co.), polyoxyethylene-polyoxypropylene glycol (e.g. Pluronic F68™ produced by Ashai Denka Kogyo K.K.), polyoxyethylene-sorbitan fatty acid ester (Tween; e.g.
Tween 80 produced by Knato Kagaku K.K.), etc.; salts such as sodium chloride, magnesium chloride, etc.; organic acids such as citric acid, tartaric acid, etc.; amino acids as glycine, β-alanine, lysine hydrochloride, etc.; and amino sugars such as meglumine. - In a preferred embodiment, a PEG is used as a gelation facilitator agent. Typically, a PEG used in the embodiments of the invention has an average molecular weight between about 4×102 daltons and about 2×104 daltons. Preferably, a PEG having an average molecular weight between about 400 daltons to about 1500 daltons is used.
- In order to insure that a drug is released into the human colon, it is desired that a portion of the preparation having undergone gelation still remain in the colon even as late as at least 6 to 8 hours, preferably at least 12 hours, after administration. To provide a tablet having such properties, although it depends on the volume of the preparation, the kind of polymer and the properties and amount of the active agent and of the gelation facilitating agent (for insuring a penetration of water into the preparation core), it is generally preferable that the formulation contains about 5 to about 85 weight %, preferably about 20 to about 70 weight %, and more preferably about 40 to about 60 weight % of the gel-forming material (e.g., the polymer and the gelation facilitator agent combined) based on the total weight of the preparation. If the amount of this polymer is less than the above-mentioned level, the preparation may not tolerate erosion in the digestive tract and may not achieve a sustained release of the active agent.
- The proportion of the gelation facilitator agent to the polymer depends on the characteristics of the active agent (solubility, therapeutic efficacy, etc.) and content of the active agent, solubility of the gelation facilitator agent itself, characteristics of the polymer used, the patient's condition at the time of administration and other factors. For administration to human patients, however, the proportion of the polymer to the gelation facilitator agent is such that the tablet can achieve a substantially complete gelation in about 4 to 5 hours after administration. Preferably, the amount of the gelation facilitator agent in the tablet is such that the tablet can achieve at least about 70%, preferably at least about 80% gelation or gelation index after two hours according to the gelation test provided in the definition section above (see, also, EP 0 661 045 A1, incorporated herein by reference). When the content of the gelation facilitator agent is too small, the necessary gelation into the core of the preparation does not proceed so that the release of the active agent in the colon becomes insufficient. On the other hand, when the content of the gelation facilitator agent is excessive, the gelation proceeds in a shorter time but the resulting gel becomes so fragile that the release of the active agent is too fast, thus failing to insure a sufficient sustained release.
- The ratios of the polymer to gelation facilitator agent are, therefore, generally between about 0.1:99.9 to about 99.9 to 0.1; between about 1:99 to about 99:1 by weight; between about 1:9 to about 9:1 by weight; between about 3:7 to about 7:3 by weight; between about 4:6 to about 6:4 by weight; or between about 3:4 to about 4:3 by weight. Typically, as the proportion of the polymer increases in the formulation, a slower rate of active agent release can be observed. With a specific combination of a polymer (i.e., PEO) and a gelation facilitator agent (i.e., PEG), however, it was observed that there is no further retardation of active agent release when the PEO content increases beyond a PEG:PEO ratio of about 3:4 to about 4:3. The release property of the active agent-containing particles can be manipulated by adjusting the polymer to gelation facilitator agent ratios in the formulation of the tablets.
- In certain embodiments, polymers such as hydroxypropylmethylcellulose (HPMC), sodium carboxymethylcellulose (CMC-Na), hydroxyethylcellulose (HEC), carboxyvinyl polymers and the like can be added to the tablet formulation to adjust and thus program the release pattern of the active agent.
- If desired, the preparation of the present invention may include appropriate amounts of other pharmaceutically acceptable additives such as vehicles (e.g., lactose, mannitol, potato starch, wheat starch, rice starch, corn starch, and crystalline cellulose), binders (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, and gum arabic), swelling agents (e.g., carboxymethylcellulose and carboxy-methylcellulose calcium), lubricants (e.g., stearic acid, calcium stearate, magnesium stearate, talc, magnesium meta-silicate aluminate, calcium hydrogen phosphate, and anhydrous calcium hydrogen phosphate), fluidizers (e.g., hydrous silica, light anhydrous silicic acid, and dried aluminum hydroxide gel), colorants (e.g., yellow iron sesquioxide and iron sesquioxide), surfactants (e.g., sodium lauryl sulfate, sucrose fatty acid ester), coating agents (e.g., zein, hydroxypropylmethylcellulose, and hydroxypropylcellulose), aromas (e.g., l-menthol, peppermint oil, and fennel oil), and preservatives (e.g., sodium sorbate, potassium sorbate, methyl p-benzoate, and ethyl-benzoate).
- Any suitable methods can be used to mix the formulation comprising the active agent-containing particles and the gel-forming materials (e.g., the polymer and the gelation facilitator). For example, direct compression or granulation (wet or dry) methods can be used.
- In one embodiment, the active agent-containing particles and the gel-forming materials are combined, and the mixture may be directly compressed into a tablet. Typically, one or more vehicles or additives may be added to the mixture to improve flow and compressible characteristics. These additives include, for example, lubricants, such as magnesium stearate, zinc stearate, stearic acid, talc and the like, flavors, or sweeteners. Direct compression has advantages, such as reducing cost, time, operational pace and machinery; preventing active agent-excipient interaction and less instability of active agent. Direct blending or slugging can also eliminate the possible pollution by organic solvent.
- In another embodiment, a wet granulation process can be used to mix one or more components of the formulation. For example, high shear granulation or fluid-bed granulation processes can be used. Any suitable commercially available granulation apparatuses can be used in these processes.
- In yet another embodiment, a dry granulation process can be used to mix one or more components of the formulation. For example, slugging or roller compaction can be used. Both wet and dry granulation processes and apparatuses are described in detail above.
- When granulation methods are used, some of the formulation components may be partially granulated prior to compression or all of the formulation components may be granulated prior to compression. For example, some or all components of the gel-forming material can be granulated prior to mixing the active agent-containing particles. In another embodiment, the polymer component (e.g., PEO) of the gel-forming material can be granulated prior to mixing with the gelation facilitator agent and/or with the particles. In yet another embodiment, the gelation facilitator agent of the gel-forming material can be granulated prior to mixing with the polymer and/or the particles. In yet another embodiment, the particles comprising an active agent can be granulated together with the gel-forming material (e.g., the polymer, the gelation facilitator agent, or both). If any of the gel-forming material is granulated first, preferably, the granules of the gel-forming material are soft or flexible enough not to damage the active agent-containing particles during compression.
- After the granulation of one or more components of the formulation, optionally, granulated formulation can be milled. Milling can be performed using any suitable commercially available apparatus (e.g., Comil equipped with a 0.039 inch screen). The mesh size for the screen can be selected depending on the size of the granules desired. After the granulated active agents are milled, they may be further dried (e.g., in the air) if desired.
- After preparing the formulation as described above, the formulation is compressed into a tablet form. This tablet shaping can be done by any suitable means, with or without compressive force. For example, compression of the formulation after the granulation step can be accomplished using any tablet press, provided that the tablet composition is adequately lubricated. The level of lubricant in the formulation is typically in the range of 0.5-2.0%, with magnesium stearate which is most commonly used as a lubricant. Other lubricants, such as zinc stearate, stearic acid, talc and the like, may also be used. Many alternative means to effect this step are available, and the invention is not limited by the use of any particular apparatus. The compression step can be carried out using a rotary type tablet press. The rotary type tableting machine has a rotary board with multiple through-holes, or dies, for forming tablets. The formulation is inserted into the die and is subsequently press-molded.
- The diameter and shape of the tablet depends on the molds, dies and punches selected for the shaping or compression of the granulation composition. Tablets can be discoid, oval, oblong, round, cylindrical, triangular, and the like. The tablets may be scored to facilitate breaking. The top or lower surface can be embossed or debossed with a symbol or letters.
- The compression force can be selected based on the type/model of press, what physical properties are desired for the tablets product (e.g., desired hardness, friability, etc.), the desired tablet appearance and size, and the like. Typically, the compression force applied is such that the compressed tablets have a hardness of at least about 2 kp. These tablets generally provide sufficient hardness and strength to be packaged, shipped or handled by the user. If desired, a higher compression force can be applied to the tablet to increase the tablet hardness. However, the compression force is preferably selected so that it does not deform (e.g., crack or break) the active agent-containing particles within the tablet. Preferably, the compression force applied is such that the compressed tablet has a hardness of less than about 10 kp. In certain embodiments, it may be preferred to compress a tablet to a hardness of between about 3 kp to about 7 kp, optionally between about 3 kp to about 5 kp, or about 3 kp.
- Typically, the final tablet will have a weight of about 100 mg to about 2000 mg, more typically about 200 mg to about 1000 mg, or about 400 mg to about 700 mg.
- If desired, other modifications can be incorporated into embodiments of the tablet. For example, modification of active agent release through the tablet matrix of the present invention can also be achieved by any known technique, such as, e.g., application of various coatings, e.g., ion exchange complexes with, e.g., Amberlite IRP-69. The tablets of the invention can also include or be coadministered with GI motility-reducing drugs. The active agent can also be modified to generate a prodrug by chemical modification of a biologically active compound which will liberate the active compound in vivo by enzymatic or hydrolytic cleavage; etc. Additional layers or coating can act as diffusional barriers to provide additional means to control rate and timing of drug release.
- IV. Manufacture of Tablets Comprising Non-Randomly Distributed Active Agents
- In another aspect, embodiments of the invention provide tablets that comprise non-randomly (e.g., not evenly) distributed active agent-containing particles By non-randomly distributing the active ingredient (or other formulation substituent) in the body of the tablet, a non-constant, but controlled level of active agent delivery can be achieved. This achieves a “programmable release profile,” such as, e.g., a pulsatile or delayed onset release profile. The tablets can also be designed and manufactured such that “lag times” of release are incorporated into this scheme. For example, the tablets can be designed to have a delayed onset release of about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, or about 7 hours, after the administration.
- In certain embodiments, the non-random active agent-containing distribution is controlled through a multilayer tablet formulation design and manufacturing process. The non-random distribution of active agent can be represented quantitatively by different amounts in different layers or qualitatively by having different forms of active agent in different layers, e.g., as having more coating materials in the particle in the outer layers as compared to the inner layers of the tablet, or, vice versa. For example, alternative layers can have, in addition to varying amounts of active agent, particles comprising the same active agent by different amounts of coating materials or different compositions of coating materials, and the like, or varying amounts of any combination of these alternative forms.
- In alternative embodiments, the non-random distribution of the active agent in the tablet is concentrated at the core of the tablet or is concentrated at the periphery of the tablet. In another embodiment, the tablet has multiple layers comprising varying amount of active agent or other formulation ingredients. Varying amounts of active agent can be in different layers of the multilayered tablet, e.g., increasing amounts of active agent in the outer layers as compared to the inner layers, or vice versa. Alternatively, different forms of active agent (e.g., encapsulated, granulated, conjugated) can be in different layers. Completely different types of active agents (e.g., drugs) or combinations thereof can be placed into different layers. The layers can be of varying thickness. Moreover, one tablet can have one, two, three, four, fix, six, seven, eight, nine, ten, or any number of layers, limited only by the desired size of the finished tablet product, the thickness of each layer, the composition of each layer's formulation, the manufacturing process, and the like.
- Various “pulsatile release” profiles can be designed by varying the rate at which the tablet dissolves as it passes through the digestive tract. This can be accomplished by manufacturing different layers of the multilayered tablet with different kinds or amounts of polymer, e.g., polymer molecular weights, different polymer to gelation facilitator agent ratios, different manufacturing compression forces, and the like. Thus, in addition to having different amounts or different modifications of active agent in each layer, the layers themselves can be pre-programmed to dissolve at different rates (and thus release active agent in different anatomical compartments) as the tablet passes through the digestive tract.
- The manufacture of the varying layers of a multilayered, pulsatile release tablet can be controlled through the compression coating process. A series of feeding devices equal in number to the number of layers to be designed in the tablet is distributed about a rotary disc (this scheme applies for both the direct compression and granulation processes). In operation, each feeding device emits a defined quantity of material into the female dies as the die travel by the feeding device's output valve. Each feeding device has a compressing device directly downstream, as seen in the direction of movement of the female dies. The compressing devices compress the material admitted into the female dies by the respective feeding devices. The compression causes the various layers of material to adhere to one another. Different amount of compressive force can be used for each layer.
- When the desired number of layers have been formed, the resulting multilayered compressed tablet is ejected from the female die. Any appropriate apparatus for forming multilayer tablets can be used to make the pulsatile release tablets of the invention. The tablet can be further processed in any suitable manner, e.g., powder layering in coating pans or rotary coaters; dry coating by double compression technique; tablet coating by film coating technique, and the like. See, e.g., U.S. Pat. No. 5,322,655;Remington 's Pharmaceutical Sciences Handbook: Chapter 90 “Coating of Pharmaceutical Dosage Forms” (1990).
- The following examples are offered by way of illustration, not by way of limitation.
- Pelletization or Granulation of Active Agent
- Cevimeline HCl crystals as purchased (from Ishihara Sangyo Kaishe, Ltd., Japan) have the following physical characteristics.
TABLE 1 Physical Characteristics of Cevimeline HCl Powder (As Received) Bulk Density ˜0.53 g/ml Tap Density (n = 400) ˜0.84 g/ml Flow (Compressibility Index) Poor (CI: ˜37%) Physical Strength of Particle Relatively Brittle Mean Particle Size ˜300 μ (˜440 μ when screened thru 60 mesh) Particle Size < Vol. % 10% 25% 50% 75% 90% Distribution Size (μ) 28 123 283 431 569 - Cevimeline HCl crystals as received were small and brittle, and were not in an optimal condition to be coated uniformly using the Wurster coating process.
- To optimize the physical characteristics of Cevimeline HCl crystals for the Wurster coating process, they were pelletized or granulated as shown in FIG. 3. Pelletization with high shear mixer granulation (HSG) and fluid-bed granulation (FBG) were investigated separately. The high shear granulator employed was Aeromatic-Field GP1/SP General Processor. The high shear granulation product was dried on a tray in the air for 1.5 hours and then milled using Comil equipped with a 0.039 inch screen. After milling, the milled pellets/granules were further dried in the air overnight. When fluid-bed granulation was used, the granulator employed was 10-GPCG-1 from Versaglatt. Two different kinds of binders, hydroxypropyl cellulose (HPC) and PEO/PEG, were also tested. The choice of the binders was based on the compatibility with the active agent. In this example, the active agent was pelletized using 10% binder (e.g., HPC) by weight. No other ingredient was added for pelletization.
- Many formulation and process parameters were studied in terms of their effect on the physical characteristics (e.g., densities/flow/size/strength) of pelletized products. Generally, the following observations were made when Cevimeline HCl crystals or powders were pelletized or granulated using the process scheme shown in FIG. 3. First, the HSG process generated the Cevimeline HCl pellets/granules of a higher density than the FBG process. The physical properties of Cevimeline HCl pellets or granules were better when HPC was used as a binder compared to using the PEO/PEG mixture as a binder. When the PEO/PEG binder was used, uniform sized pellets were not made but big sized lumps were partly formed. This result may be due to the different wetting behaviors of PEO and PEG. Moreover, it was observed that when the aqueous binder solution is highly viscous, it may be difficult to achieve a uniform spray pattern. For example, when the HPC was used as a binder, it was found that it was easier to obtain evenly distributed active agent granules when HPC powder and the active agent were blended first and then water was sprayed on to achieve a uniform pattern.
- The physical characteristics of the active pellets/granules produced by the HSG process using HPC as a binder were found to have the following features:
TABLE 2 Physical Characteristics of Active Pellets Prepared by HSG (n = 4). Bulk Density 0.64 ± 0.01 g/ml Tap Density (n = 400) 0.71 ± 0.01 g/ml Flow (Compressibility Index) Good (CI: 8-10%) Physical Strength of Particle Relatively Strong Mean Particle Size* 566 μ Particle Size < Vol. % 10% 25% 50% 75% 90% Distribution* Size (μ) 290 393 542 716 888 - As shown in the above tables, flow and physical strength are greatly improved and mean particle size is greatly increased by the HSG. The particle shape of active pellets was observed to be round using optical microscopy. From the experimental coating trials, it was concluded that the active agent pellets are much better than the active crystals (as purchased) for the Wurster coating process.
- The yield of this HSG process was greater than 90%. Each pelletization product was analyzed using an HPLC method to figure out active content. The HPLC assay showed an active content range of 89.5-90.3%, which is virtually identical to the formulated content. This result indicates that the high shear pelletization was well carried out as designed.
- The active Cevimeline pellets prepared by the HSG process were coated with coating agents using GPCG-1 (230-VG Versa Glatt,
screen size 100 μ) equipped with Wurster column (diameter 71 mm, partition 1.75 inches). An overview for the coating process development of active pellets is presented in FIG. 4. Three different aqueous polymeric dispersions, Surelease® (ethyl cellulose), Eudragit™ RS/NE (polyacrylic polymers) and Kollicoat® SR (polyvinylacetate), were examined in terms of the ability of each polymer to form hydrophobic flexible coating membrane. Their formulations were also developed to accommodate effective coating process. - Generally, the following observations were made with these three coatings on the Cevimeline pellets. The Wurster coating process for the Cevimeline pellets using Surelease® or Kollicoat® provided a more effective process and a more uniform coating than using Eudragit™ NE or RS as a coating material. Eudragi™ NE or RS had a tendency to stick and agglomerate active agent pellets. Relatively high tack of its formula also led to relatively frequent clogging of the nozzle of spray system.
- The following tablets illustrate the formulations developed for the Surelease® and Kollicoat® coating of active agent pellets. The formulation is based on using 50% coating. This % coating means % ratio of the amount of coating polymer by weight used to the amount of active agent pellets given (including HPC). For example, in Table 3,500 grams of active pellets were coated with 1008.1 gram of 24.8% dispersion of Surelease® E-7-19010. Thus, the 50% coating on the active pellets in this example is calculated by multiplying 1008.1 gram by 24.8% (weight of coating polymer), divided by 500 grams (weight of active pellets).
TABLE 3 Formulation for 50% Surelease ® Coating of 500 g Active Pellets As A Typical Example. Surelease ® E-7-19010* 1008.1 g 20.0%** Coating Polymer (24.8% dispersion) DI-Water 241.9 g 80.0% For Dilution to 20% Total 1250.0 g 100.0% -
TABLE 4 Formulation for 50% Kollicoat ® SR Coating of 500 g Active Pellets As A Typical Example. Kollicoat ® SR 30 D* 833.3 g 20.0%** Coating Polymer (30.0% dispersion) Talc 12.5 g 1.0% Glidant (5% of polymer) DI-Water 404.2 g 79.0% For Dilution to 20% Total 1250.0 g 100.0% - The processing parameters were optimized for both coatings. Twenty %(w/w) solid concentration of both the Surelease® and Kollicoat® coating formula (based on the total tablet preparation weight) was found to be most effective for the process. No significant difficulties were observed when both coatings were tried up to 100% coating.
- Table 5 illustrates the changes in the physical properties of the Surelease® or Kollicoat® coated active agent-containing particles compared to the physical properites of the active agent pellets without coating (shown in Table 2).
TABLE 5 Changes (Trend) in the Physical Properties of Active Particles after Surelease ® or Kollicoat ® Coating Bulk Density Increased by ˜0.05-0.1 g/ml Tap Density (n = 400) Slightly Increased by ˜0.02-0.8 g/ml Flow Not Significantly/Slightly Better Flow Compressibility Index CI: Slightly Decreased by ˜2-4% Mean Particle Size Significantly Increased Particle Shape/Surface Round and Even/Smooth and Flexible Physical Strength of Particle Relatively strong and Flexible - FIG. 6 also shows that mean particle size of coated particles increased substantially as % coating was increased. These results indicate that the particulate coatings were well processed from the viewpoint of physical characteristics. The yield of Wurster process was always higher than 90%.
- In vitro drug release studies for the active agent-containing particles (also referred to as “coated bead” or “coated particle”) were carried out using USP II dissolution apparatus (Hanson Research Automated Sampling System) at 75 rpm paddle speed. Coated particle samples were placed into dissolution vessels containing 900 ml of degassed DI water at 37° C. No dissolution medium replacement was made at each sampling but the volume correction was done in calculating drug content. The amount of drug released from bead was measured using an UV-Visible spectrophotometer (Hewlett Packard) at 243 nm.
- The dissolution profiles of Surelease® coated particles (that are prepared as described above) are presented in FIG. 7. No significant variations were found among the bead samples from a coating batch. These results indicate that the active agent pellets were uniformly and effectively coated. As shown in FIG. 7, the drug release was gradually prolonged as coating amount (% coating) was increased. This implies that the increased % coating results in the increased thickness of the hydrophobic polymeric film. Thus, the drug release rate decreased as the diffusion membrane was thickened. Similar results were observed for Kollicoat® coated particles.
- However, as shown in FIG. 8, three randomly selected PEO/PEG matrix tablets containing Kollicoat® coated beads showed a significant content non-uniformity. Each of these tablets weighs 606 mg and is 11.1 mm round/concave shaped. Their drug release profiles did not reach 100% up to 24 hours. However, there was a 43.5% deviation in % drug released among the randomly sampled three tablets. Thus, Kollicoat® coating may not be an optimal formulation for coating Cevimeline HCl using the Wurster coating process.
- The design of a gel-forming matrix requires several considerations. These include, e.g., how gel-forming material or matrix formers (e.g., a polymer and a gelation facilitator agent) can be effectively prepared, how the matrix formers can be uniformly blended with coated beads, and then how the final blend can be compressed into matrix tablets with no damage of coated beads.
- In this example, a polyethylene oxide polymer (i.e., PEO WSR 303 from Union Carbide, Danbury, Conn., USA, MW=7,000,000 daltons) and a polyethylene glycol (i.e., PEG from Union Carbide, Danbury, Conn., USA, MW=8,000 daltons) were used as components of the gel-forming material. Per tablet, 229.0 mg of PEO and 172.0 mg of PEG were used (the PEO/PEG ratio of 4:3 w/w). The physical properties of PEO/PEG powder blend are shown in a following table (n=2):
TABLE 6 Physical Properties of PEO/PEG Powder Blend Bulk Density 0.53 ± 0.001 g/ml Tap Density (n = 400) 0.59 ± 0.002 g/ml Flow (Compressibility Index) Good (CI: ˜10%) Particle Size 100-150 μ - The bulk density and particle size of PEO/PEG powder blend are quite different from those of coated particles (see Tables 2 and 5). To achieve uniformity, the PEO/PEG powder mixture was physically modified to have similar physical characteristics to those of the Surelease® or Kollicoat® coated particles. In other words, the bulk density and particle size of the PEO/PEG powder mixture were increased to achieve uniform blending with the coated particles comprising Cevimeline.
- The physical modification could be made through dry or wet granulation of PEO/PEG either in the presence or in the absence of coated particles. In the case of the granulation of PEO/PEG with coated particles, the granulation will include a blending procedure. The PEO/PEG granules need to be soft (or flexible) enough not to damage the coated particles during compression. The granules must also serve as a filler of the matrix.
- FIG. 5 shows the overview for both the process development of PEO/PEG granulation and the compression of the final blend with coated drug. The physical characteristics for both coated beads and PEO/PEG granules were evaluated in terms of blending uniformity, compressibility and content uniformity of final tablets.
- In the initial studies, the following observations were made. The granules generated by HSG looked good-shaped (round) and pretty dense, but were too hard and low in compressibility. Thus, the PEO/PEG granules generated by HSG were not optimal for mixing with the coated particles comprising Cevimeline. The roller compaction dry granulation of PEO/PEG powder resulted in PEO/PEG granules that mixed well with the coated particles comprising Cevimeline. Moreover, the fluid-bed granulation without coated particles generated relatively soft and flexible PEO/PEG granules. However, the granules were too light (approximately half value of bulk density of coated particles). The fluid-bed granulation of PEO/PEG with coated particles was found to be relatively desirable in terms of blending uniformity and compressibility.
- A. Roller Compaction Dry Granulation (RCDG)
- The roller compaction process of the PEO/PEG powder blend was optimized. The roller compactor used is Fitzpatrick IR 220 Chilsonator. The roller compaction was directly followed by milling. The compacted ribbons were milled using a M5A Fitz Mill equipped with traditional blade rotor and 0.065 inches screen. The characterized properties of the RCDG product are shown in Table 7. The blending between the granules and the Surelease® coated beads was observed to be relatively uniform. The V-blender used is a P-K Blend Master. The formulation is presented in Table 8.
TABLE 7 Physical Characteristics of PEO/PEG Granules Prepared by RCDG (A Typical Case) After Milling After Screening* Bulk Density 0.51 g/ml 0.50 g/ml Tap Density (n = 400) 0.62 g/ml 0.63 g/ml Compressibility Index 17% 21% Physical Strength of Particle Brittle Brittle Mean Particle Size* ˜615 μ ˜230 μ -
TABLE 8 Tableting Formulation for the Final Blend of Surelease ® Coated Active Beads and PEO/PEG Granules Prepared by RCDG. PEO/PEG Granule 230.0 mg 56.9% Matrix Former 70% Surelease Coated Bead* 170.0 mg 42.1% Coated Drug Magnesium Stearate 4.0 mg 1.0% Lubricant Total 404.0 mg 100.0% - It was observed that the dissolution profile of Surelease® coated particle in the gel-forming matrix prepared by RCDG did not achieve 18-24 hours extension of drug release. Not wishing to be bound by a theory, this may be due to the possibility that the coated beads were partially damaged by the relatively hard granules made by RCDG.
- B. Fluid-Bed Wet Granulation with Top-Spray Technique (FBG)
- GPCG-1 Versa Glatt with top-spray set was used for the fluid-bed granulation of PEO/PEG in the presence of coated drug. A formulation for a given tablet size (606 mg including 1% magnesium stearate) is presented as an example in Table 9. Table 10 lists changes to the physical characteristics after the FBG process. Prior to compression, the FBG product was blended again with the P-K V-blender for 5 minute to increase blending uniformity and mixed with magnesium stearate for additional 2 minutes.
TABLE 9 Formulation for the fluid-bed granulation of PEO/PEG and a 100% Surelease ® coated drug 100% Surelease Coated Bead* 199.0 mg (90 mg of Active) PEO (Polyox WSR303) 229.0 mg PEG 8000 172.0 mg DI-water** 20% of total amount of polymers Total 600.0 mg (Batch Size: 750 g) -
TABLE 10 Changes (Trend) in the Physical Properties after the Fluid-Bed Granulation of PEO/PEG and Coated Drug (Compared to Coated Particles) Bulk Density Decreased (˜0.45-0.55 g/ml) Tap Density (n = 400) Decreased (˜0.53-0.63 g/ml) Flow Not Significantly Changed Compressibility Index CI: 9-14% Blending Uniformity Visually Well-Blended Appearance of Coated Beads Visually Not Damaged Mean Particle Size Decreased Particle Size < Vol. % 10% 25% 50% 75% 90% Distribution* Size (μ) 154 265 458 726 1071 - The following observations were made. Relatively fluffy and bouncy PEO/PEG granules smaller than the coated particles were generated separately from the coated particles. Some PEO/PEG granules were adhered to the coated particles to form agglomerates. This led to the most uniform blending between PEO/PEG and coated particles. The blending was most effective and uniform when fluid-bed granulation (with top-spray technique) was used for PEO/PEG in the presence of coated particles.
- The change to particle size distribution is evidential enough to back up the above observation. As shown in Table 10, the particle size distribution of the granulation product is wide; bigger and smaller size distributions may represent the agglomerates of PEO/PEG and coated drug and PEO/PEG granules or coated particles only, respectively.
- The final blends (those produced by fluid bed granulation by mixing PEO/PEG in the presence of coated particles) were compressed into tablets using PH-106-DMS Korsch rotary tablet press. Three different tablet toolings were individually mounted to the press, depending upon the tablet size and shape designed; 9.5 mm round/concave tooling for 404 mg tablet, 11.1 mm round/concave and 8.7×18.9 mm oval toolings for 606 mg tablet. Different compression forces yielding different hardness were tested to balance two requirements—physical stability of the tablets and minimal damage to the coated particles by the compressive force.
- The results from the initial studies were as follows.
- First, compression force appears to influence the drug release of the coated bead in matrix dosage form. The Surelease® coated particle containing matrix tablets compressed at 3 kp were more effective in drug release than those at 5 kp or 7 kp. These results may be associated with the safety of coating membrane against the compression force applied and the compactness of matrix by the compression force applied.
- Second, tablet shape does not appear to affect drug release significantly.
- Third, the total tablet weight appears to influence the drug release profile. In making tablets of varying total tablet weight, the amount of the coated particles was fixed and the amount of the gel-forming material was changed (% content of matrix formers). The PEO:PEG ratio was maintained at 4:3 for all tablets. For instance, the tablet that weighs 404 mg contained 199 mg of active agent-containing particles, 115 mg of PEO, 86 mg of PEG, and 6 mg of magnesium stearate; and the tablet that weighs '606 mg contained 199 mg active agent-containing particles, 229 mg of PEO, 172 mg of PEG, and 6 mg of magnesium stearate. When the tablet weight was changed from 404 mg to 606 mg, the drug release rate was found to decrease over time for the Surelease® coated particles in matrix tablets. For instance, the tablets that weigh 404 mg showed 96% drug release for 12 hours in the case of Surelease® coated particle, while the tablets that weigh 606 mg showed only 83% release.
- A. Dissolution Test Method
- In vitro drug release studies for these matrix tablets were conducted using USP II dissolution apparatus (Hanson Research SK8 PLUS Auto Plus Maximizer and Autofiller) at 75 rpm paddle speed. Each tablet sample was put into a sinker, and the sinker was then placed into dissolution vessel containing 900 ml of degassed DI water at 37° C. No dissolution medium replacement was made at each sampling but the volume correction was done in calculating drug content. The amount of drug released from matrix tablet was measured using HPLC (Hewlett Packard Series 1100).
- B Dissolution Performance of Tablets Comprising Untreated Active Agent
- The tablets comprising Cevimeline HCl (Ishihara Sangyo Kaishe, Ltd., Japan) as an active agent without any coating (“conventional” Cevimeline tablets) were manufactured by direct blending the following ingredients: 90 mg active agent; PEO WSR 303 (Union Carbide, Danbury, Conn., USA); PEG 8000 (Union Carbide, Danbury, Conn., USA) (PEO/PEG ratio=4:3) and 1% magnesium stearate (Mallinckrodt, St. Louis, Mo., USA) together, then compressing the final blend into tablets that weigh 404 mg using Korsch press. Each tablet contained 90 mg pure untreated active agent, 177 mg of PEO and 133 mg of PEG, and 4 mg of magnesium stearate.
- FIG. 9 illustrates the drug release profile from conventional Cevimeline HCl matrix tablets. As shown in FIG. 9, Cevimeline was released in about 6 hours, and could not achieve 12-24 hour sustained release. This result illustrates that the gel matrix system alone is not sufficient to provide a sustained release of a hydrophilic active agent for up to 12-24 hours.
- C. Dissolution Performance of Tablets Comprising Coated Particles
- FIG. 10 illustrates the drug release profiles from two different shaped 606 mg tablets comprising 100% Surelease® coated particles in PEO/PEG gel-forming matrix prepared by fluid-bed granulation (HPLC Method). One set of tablets were round/concave and were 11.1 mm in their dimension. The two different shaped tablets were made using the same batch of 100% Surelease® coating. The other set of tablets were oval and were 8.7×18.9 mm in dimension. As shown in FIG. 10, both round and oval shaped tablets had 24 hours sustained drug release in water at 37° C. No significant difference in drug release profile was found between the round and oval tablets.
- The deviation among the drug release profiles for both kinds of tablets was observed to be very small. The maximum standard deviation was 5.1% in % drug release. This result indicates that the content uniformity is acceptable, which is consistent with the blending uniformity verified through visual observation.
- Therefore, the 100% Surelease® coated particle in the gel-forming matrix dosage form provides 18-24 hours extended release of Cevimeline HCl. Moreover, the results meet a desirable dissolution specification, wherein no more than 40% released at 1 hour, 75+15% released at 12 hours, and no less than 80% released at 24 hours.
- This example demonstrates that tablets of the invention incorporating Cardizem SR pellets (diltiazem hydrochloride; Hoechst Marion Roussel) in the core of tablet produce an in vivo delayed release (delayed dissolution) profile.
- The tablets were compressed using Carver press with ⅜ inch concave punches and dies by direct compression. First, a layer of PEO/PEG mixture (PEO/PEG ratio=4:3) was placed in the die. Second, Cardizem SR pellets were manually placed on top of the first layer in the core region of the mixture. Third, another layer of PEO/PEG mixture was then put on top of the pellets to maintain the active agent-containing pellets in the core region. Finally, the tablet was compressed with the pellets in the core.
- In vitro drug release studies were carried out using the USP apparatus II as described above and using the USP apparatus II at a paddle speed of 100 rpm in 500 ml dissolution medium at 37° C. Samples were assayed using a Uv-VIS spectrophotometer at a wavelength of 210 nm.
- As shown in FIG. 11, an approximately 5 hours delay of onset of drug dissolution was observed with the Cardizem SR pellets in core of this tablet.
- The present invention provides novel materials and methods for producing tablets. While specific examples have been provided, the above description is illustrative and not restrictive. Any one or more of the features of the previously described embodiments can be combined in any manner with one or more features of any other embodiments in the present invention. Furthermore, many variations of the invention will become apparent to those skilled in the art upon review of the specification. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.
- All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted. By their citation of various references in this document, Applicants do not admit any particular reference is “prior art” to their invention.
Claims (51)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/191,979 US20030108602A1 (en) | 2000-05-19 | 2002-07-08 | Tablets and methods for modified release of hydrophilic and other active agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/599,102 US6419954B1 (en) | 2000-05-19 | 2000-05-19 | Tablets and methods for modified release of hydrophilic and other active agents |
US10/191,979 US20030108602A1 (en) | 2000-05-19 | 2002-07-08 | Tablets and methods for modified release of hydrophilic and other active agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/599,102 Continuation US6419954B1 (en) | 2000-05-19 | 2000-05-19 | Tablets and methods for modified release of hydrophilic and other active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030108602A1 true US20030108602A1 (en) | 2003-06-12 |
Family
ID=24398223
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/599,102 Expired - Lifetime US6419954B1 (en) | 2000-05-19 | 2000-05-19 | Tablets and methods for modified release of hydrophilic and other active agents |
US10/191,979 Abandoned US20030108602A1 (en) | 2000-05-19 | 2002-07-08 | Tablets and methods for modified release of hydrophilic and other active agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/599,102 Expired - Lifetime US6419954B1 (en) | 2000-05-19 | 2000-05-19 | Tablets and methods for modified release of hydrophilic and other active agents |
Country Status (6)
Country | Link |
---|---|
US (2) | US6419954B1 (en) |
EP (1) | EP1286662A4 (en) |
JP (1) | JP4853695B2 (en) |
AU (1) | AU2001263264A1 (en) |
CA (1) | CA2409292C (en) |
WO (1) | WO2001089483A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036856A1 (en) * | 2005-08-11 | 2007-02-15 | Cheng Xiu X | Diltiazem controlled release formulation and method of manufacture |
US20090049935A1 (en) * | 2005-06-10 | 2009-02-26 | Pierre Fabre Medicament | Stabilized milnacipran formulation |
US20100047337A1 (en) * | 2006-03-16 | 2010-02-25 | Euro-Celtique S.A. | Pharmaceutical spheroids |
US20100102474A1 (en) * | 2006-11-13 | 2010-04-29 | Kyorin Pharmaceutical Co., Ltd. | Method for preparing sustained release tablet |
WO2012056471A2 (en) * | 2010-10-24 | 2012-05-03 | Shasun Pharmaceuticals Limited | Novel process for preparing dexibuprofen ready to compress granules |
EP3257574A1 (en) * | 2016-06-15 | 2017-12-20 | Clariant International Ltd | Method for producing a particle-shaped material |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
AU2001279284A1 (en) * | 2000-07-05 | 2002-01-14 | Capricorn Pharma, Inc | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
CN101317825A (en) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
CN1212126C (en) * | 2002-07-09 | 2005-07-27 | 中国科学院长春应用化学研究所 | Nano hydroxy apatite calcium supplementing agent |
FR2845289B1 (en) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS. |
CA2406592C (en) * | 2002-10-04 | 2003-09-30 | Duchesnay Inc. | Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
AU2003284962B2 (en) * | 2002-10-24 | 2009-04-02 | Palmetto Pharmaceuticals, Llc | Sustained release L-arginine formulations and methods of manufacture and use |
WO2005035001A1 (en) * | 2003-09-29 | 2005-04-21 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
JP2004307398A (en) * | 2003-04-07 | 2004-11-04 | National Institute For Materials Science | Medicament-encapsulated multilayer-structured microparticle |
US20050042289A1 (en) * | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
US20050013897A1 (en) * | 2003-07-14 | 2005-01-20 | Meyer John M. | Long-lasting crustacean bait for use in traps and method of making the same |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
ES2734057T3 (en) * | 2003-09-12 | 2019-12-04 | Amgen Inc | Rapid dissolution formulation comprising cinacalcet HCl |
US7051606B2 (en) * | 2004-01-30 | 2006-05-30 | Andrx Labs Llc | Dosage form holder device and methods for immersion testing |
JP2005306778A (en) * | 2004-04-21 | 2005-11-04 | Basf Ag | Sustained-release formulation and method for producing the same |
MXPA06013397A (en) * | 2004-05-21 | 2007-01-23 | Alza Corp | Dosage form for delivery of multiple drug forms. |
HUE037643T2 (en) | 2004-06-12 | 2018-09-28 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
US9308164B2 (en) * | 2004-06-30 | 2016-04-12 | Sovereign Pharmaceuticals, Llc | Hyoscyamine dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
WO2006078320A2 (en) | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
UA95093C2 (en) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Method for the preparation of calcium-containing compound |
BRPI0709606B8 (en) | 2006-03-16 | 2021-05-25 | Tris Pharma Inc | orally administrable liquid suspension with modified release characteristics |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
WO2008002529A2 (en) * | 2006-06-26 | 2008-01-03 | Capricorn Pharma, Inc. | Orally disintegrating layered compositions |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
WO2008123775A1 (en) * | 2007-04-06 | 2008-10-16 | Sara Lee/De N.V. | Method for manufacturing a coffee tablet, and a coffee tablet for preparing coffee obtained with such method |
US8273798B2 (en) * | 2007-06-04 | 2012-09-25 | Shear Kershman Laboratories | Tamper resistant lipid-based oral dosage form for opioid agonists |
CN105534936B (en) | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | Abuse resistant drugs, methods of use and methods of preparation |
WO2009028598A1 (en) | 2007-08-31 | 2009-03-05 | Daiichi Sankyo Company, Limited | Sustained release preparation and process for production thereof |
ES2718612T3 (en) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedure for preparing microparticles that have a low volume of residual solvent |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US7662858B2 (en) * | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
US8420700B1 (en) * | 2008-06-04 | 2013-04-16 | James M. Bausch | Tamper resistant lipid-based oral dosage form for sympathomimetic amines |
US20110195121A1 (en) * | 2008-06-19 | 2011-08-11 | Seshni Sewlall | chronotherapeutic pharmaceutical dosage form |
PE20120572A1 (en) | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | HANDLING RESISTANT STABILIZED OXIDATION DOSAGE FORM |
EP2456427B1 (en) | 2009-07-22 | 2015-03-04 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP2531176B1 (en) | 2010-02-03 | 2016-09-07 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
TR201802207T4 (en) | 2010-03-29 | 2018-03-21 | Astellas Pharma Inc | Controlled Release Pharmaceutical Composition. |
GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
MX2012012991A (en) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Alcoholres i stant metoprolol - containing extended - release oral dosage forms. |
PE20131126A1 (en) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
ES2643291T3 (en) | 2010-12-22 | 2017-11-22 | Purdue Pharma L.P. | Controlled release dosage forms with inviolable closure coated |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
RU2671575C2 (en) | 2011-05-10 | 2018-11-02 | Теравида, Инк. | Appliance of solifenacin and saliva flow stimulators for the treatment of overactive bladder |
DK2736497T3 (en) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Shock-resistant tablet that provides an immediate release of a drug. |
EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
LT2838512T (en) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9717741B2 (en) | 2012-10-11 | 2017-08-01 | Anaplasi Pharmaceuticals Llc | Method and compositions for treating psoriasis |
JP6059352B2 (en) | 2012-10-11 | 2017-01-11 | アナプラシ ファーマシューティカルズ エルエルシー | Methods and compositions for treating psoriasis |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
MX2017007493A (en) * | 2014-12-17 | 2018-01-26 | Empros Pharma Ab | A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders. |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
JP2019503273A (en) * | 2015-12-17 | 2019-02-07 | ミスライ アクシヨテ、アルド アドルフォ | System for mass transfer with solids capture via induction of electromagnetic fields |
BR112018014661A2 (en) | 2016-01-20 | 2018-12-11 | Theravida Inc | composition and composition for use |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
US10874741B2 (en) | 2017-08-28 | 2020-12-29 | Spectrix Therapeutics, LLC | Compound to treat Sjogren's syndrome |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
WO2019070581A1 (en) * | 2017-10-02 | 2019-04-11 | Purdue Pharma L.P | Pharmaceutical compositions comprising delayed release gelling agent compositions |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
EP4284347A1 (en) | 2021-01-28 | 2023-12-06 | Galvita AG | Solid pharmaceutical compositions and methods of producing the same |
EP4311543A1 (en) | 2022-07-27 | 2024-01-31 | Galvita AG | Methods for loading template inverted carriers |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404183A (en) * | 1979-07-05 | 1983-09-13 | Yamanouchi Pharmaceutical Co., Ltd. | Sustained release pharmaceutical composition of solid medical material |
US4767378A (en) * | 1985-08-01 | 1988-08-30 | Siemens Aktiengesellschaft | Frontal magnet coupling with integrated magnetic bearing load relief |
US4806337A (en) * | 1984-07-23 | 1989-02-21 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5322655A (en) * | 1993-02-19 | 1994-06-21 | Thomas Engineering, Inc. | Method for monitoring and controlling the weights of each layer of a multilayer tablet |
US5370879A (en) * | 1990-02-11 | 1994-12-06 | Elan Corporation, Plc | Formulations and their use in the treatment of neurological diseases |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
US5676972A (en) * | 1995-02-16 | 1997-10-14 | The University Of Akron | Time-release delivery matrix composition and corresponding controlled-release compositions |
US5766623A (en) * | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US5834023A (en) * | 1995-03-24 | 1998-11-10 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation |
US5846563A (en) * | 1993-09-09 | 1998-12-08 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5851552A (en) * | 1994-06-14 | 1998-12-22 | Fuisz Technologies, Ltd. | Delivery of controlled-release system(s) |
US5908638A (en) * | 1995-07-26 | 1999-06-01 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US6024982A (en) * | 1993-11-23 | 2000-02-15 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6294201B1 (en) * | 1997-10-12 | 2001-09-25 | Bayer Aktiengesellschaft | Osmotic medicament releasing system |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE575775A (en) * | 1958-02-18 | |||
GB1598458A (en) * | 1977-04-01 | 1981-09-23 | Hoechst Uk Ltd | Tableting of microcapsules |
JPS62120315A (en) * | 1985-11-20 | 1987-06-01 | Shin Etsu Chem Co Ltd | Production of sustained release tablet |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
NZ223619A (en) * | 1987-02-27 | 1990-10-26 | Lilly Co Eli | Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer |
US4925675A (en) * | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
KR100355130B1 (en) | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | Hydrogel Sustained Release Tablet |
WO1998019667A1 (en) * | 1996-11-01 | 1998-05-14 | Ilex Oncology, Inc. | Sustained release formulation containing dfmo |
AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
-
2000
- 2000-05-19 US US09/599,102 patent/US6419954B1/en not_active Expired - Lifetime
-
2001
- 2001-05-18 AU AU2001263264A patent/AU2001263264A1/en not_active Abandoned
- 2001-05-18 EP EP01937545A patent/EP1286662A4/en not_active Withdrawn
- 2001-05-18 WO PCT/US2001/016137 patent/WO2001089483A1/en active Application Filing
- 2001-05-18 CA CA002409292A patent/CA2409292C/en not_active Expired - Fee Related
- 2001-05-18 JP JP2001585728A patent/JP4853695B2/en not_active Expired - Fee Related
-
2002
- 2002-07-08 US US10/191,979 patent/US20030108602A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404183A (en) * | 1979-07-05 | 1983-09-13 | Yamanouchi Pharmaceutical Co., Ltd. | Sustained release pharmaceutical composition of solid medical material |
US4806337A (en) * | 1984-07-23 | 1989-02-21 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4767378A (en) * | 1985-08-01 | 1988-08-30 | Siemens Aktiengesellschaft | Frontal magnet coupling with integrated magnetic bearing load relief |
US5370879A (en) * | 1990-02-11 | 1994-12-06 | Elan Corporation, Plc | Formulations and their use in the treatment of neurological diseases |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5322655A (en) * | 1993-02-19 | 1994-06-21 | Thomas Engineering, Inc. | Method for monitoring and controlling the weights of each layer of a multilayer tablet |
US5846563A (en) * | 1993-09-09 | 1998-12-08 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6024982A (en) * | 1993-11-23 | 2000-02-15 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5851552A (en) * | 1994-06-14 | 1998-12-22 | Fuisz Technologies, Ltd. | Delivery of controlled-release system(s) |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
US5676972A (en) * | 1995-02-16 | 1997-10-14 | The University Of Akron | Time-release delivery matrix composition and corresponding controlled-release compositions |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US5834023A (en) * | 1995-03-24 | 1998-11-10 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation |
US5908638A (en) * | 1995-07-26 | 1999-06-01 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US5766623A (en) * | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US6294201B1 (en) * | 1997-10-12 | 2001-09-25 | Bayer Aktiengesellschaft | Osmotic medicament releasing system |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309128B2 (en) * | 2005-06-10 | 2012-11-13 | Pierre Fabre Medicament | Stabilized milnacipran formulation |
US20090049935A1 (en) * | 2005-06-10 | 2009-02-26 | Pierre Fabre Medicament | Stabilized milnacipran formulation |
US20070036856A1 (en) * | 2005-08-11 | 2007-02-15 | Cheng Xiu X | Diltiazem controlled release formulation and method of manufacture |
US8778395B2 (en) | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
US20100047337A1 (en) * | 2006-03-16 | 2010-02-25 | Euro-Celtique S.A. | Pharmaceutical spheroids |
US9034373B2 (en) * | 2006-03-16 | 2015-05-19 | Euro-Celtique S.A. | Pharmaceutical spheroids |
US20100102474A1 (en) * | 2006-11-13 | 2010-04-29 | Kyorin Pharmaceutical Co., Ltd. | Method for preparing sustained release tablet |
US8202456B2 (en) * | 2006-11-13 | 2012-06-19 | Kyorin Pharmaceutical Co., Ltd. | Method for preparing sustained release tablet |
WO2012056471A3 (en) * | 2010-10-24 | 2012-06-21 | Shasun Pharmaceuticals Limited | Preparing dexibuprofen ready-to-compress granules |
WO2012056471A2 (en) * | 2010-10-24 | 2012-05-03 | Shasun Pharmaceuticals Limited | Novel process for preparing dexibuprofen ready to compress granules |
EP3257574A1 (en) * | 2016-06-15 | 2017-12-20 | Clariant International Ltd | Method for producing a particle-shaped material |
WO2017215963A1 (en) * | 2016-06-15 | 2017-12-21 | Clariant International Ltd | Method for producing a particle-shaped material |
CN109475832A (en) * | 2016-06-15 | 2019-03-15 | 科莱恩国际有限公司 | Method for producing granular material |
Also Published As
Publication number | Publication date |
---|---|
WO2001089483A1 (en) | 2001-11-29 |
CA2409292A1 (en) | 2001-11-29 |
JP4853695B2 (en) | 2012-01-11 |
EP1286662A1 (en) | 2003-03-05 |
JP2003534269A (en) | 2003-11-18 |
EP1286662A4 (en) | 2009-08-05 |
AU2001263264A1 (en) | 2001-12-03 |
WO2001089483A9 (en) | 2003-03-06 |
US6419954B1 (en) | 2002-07-16 |
CA2409292C (en) | 2008-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6419954B1 (en) | Tablets and methods for modified release of hydrophilic and other active agents | |
KR100355130B1 (en) | Hydrogel Sustained Release Tablet | |
AU2005237411B2 (en) | Orally disintegrating tablets and methods of manufacture | |
EP1523994B1 (en) | Medicinal composition for regulating release and process for producing the same | |
US20060088594A1 (en) | Highly compressible controlled delivery compositions of metformin | |
EP1491184B1 (en) | Soft tablet containing high molecular weight cellulosics | |
US20100151019A1 (en) | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF | |
JP2002533380A (en) | Dosage form containing porous particles | |
WO2008062470A2 (en) | Stabilized controlled release dosage form of gliclazide | |
US20040265373A1 (en) | Soft tablet containing high molecular weight cellulosics | |
US20050118256A1 (en) | Extended release alpha-2 agonist pharmaceutical dosage forms | |
KR20080059212A (en) | 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation | |
JP3598049B2 (en) | Hydrogel sustained release formulation | |
US20050042289A1 (en) | Tablets and methods for modified release of hydrophylic and other active agents | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
WO2020249500A1 (en) | Stable tablet formulation of nifurtimox and process for producing the same | |
CA2472432C (en) | Soft tablet containing high molecular weight cellulosics | |
MX2011005128A (en) | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTELLAS PHARMA TECHNOLOGIES, INC.,OKLAHOMA Free format text: CHANGE OF NAME;ASSIGNOR:YAMANOUCHI PHARMA TECHNOLOGIES, INC.;REEL/FRAME:019116/0039 Effective date: 20050401 Owner name: ASTELLAS PHARMA TECHNOLOGIES, INC., OKLAHOMA Free format text: CHANGE OF NAME;ASSIGNOR:YAMANOUCHI PHARMA TECHNOLOGIES, INC.;REEL/FRAME:019116/0039 Effective date: 20050401 |
|
AS | Assignment |
Owner name: ASTELLAS PHARMA INC.,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTELLAS PHARMA TECHNOLOGIES, INC.;REEL/FRAME:019407/0775 Effective date: 20070427 Owner name: ASTELLAS PHARMA INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTELLAS PHARMA TECHNOLOGIES, INC.;REEL/FRAME:019407/0775 Effective date: 20070427 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |